<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Nasal decongestants in monotherapy for the common cold - Deckx, L - 2016 | Cochrane Library</title> <meta content="Nasal decongestants in monotherapy for the common cold - Deckx, L - 2016 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Nasal decongestants in monotherapy for the common cold - Deckx, L - 2016 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD009612.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Nasal decongestants in monotherapy for the common cold" name="citation_title"/> <meta content="Laura Deckx" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="An IM De Sutter" name="citation_author"/> <meta content="Ghent University" name="citation_author_institution"/> <meta content="Linda Guo" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Nabiel A Mir" name="citation_author"/> <meta content="The University of Queensland" name="citation_author_institution"/> <meta content="Mieke L van Driel" name="citation_author"/> <meta content="m.vandriel@uq.edu.au" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="10" name="citation_issue"/> <meta content="10.1002/14651858.CD009612.pub2" name="citation_doi"/> <meta content="2016" name="citation_date"/> <meta content="2016/10/17" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009612.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Administration, Intranasal; Common Cold [*drug therapy]; Imidazoles [administration &amp; dosage]; Nasal Decongestants [*administration &amp; dosage, adverse effects]; Oxymetazoline [administration &amp; dosage]; Phenylpropanolamine [administration &amp; dosage]; Pseudoephedrine [administration &amp; dosage]; Randomized Controlled Trials as Topic; Time Factors" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD009612.pub2&amp;doi=10.1002/14651858.CD009612.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774054000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739774081000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1559916434000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1559916434000"}};Liferay.authToken="kKvAiZoF";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD009612\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD009612\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1559916434000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","zh_HANS","ru","ms","hr","fr","pl","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD009612.pub2",title:"Nasal decongestants in monotherapy for the common cold",firstPublishedDate:"Oct 17, 2016 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Acute Respiratory Infections Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738735355000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009612.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009612.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD009612.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD009612.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009612.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD009612.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Abstract&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;pl&quot;,&quot;title&quot;:&quot;Streszczenie prostym językiem&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;Plain language summary&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Conclusiones de los autores&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Antecedentes&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Objetivos&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Métodos&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Discusión&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD009612.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD009612.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD009612.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD009612.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>11474 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD009612.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0159"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0060"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-sec-0153"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/appendices#CD009612-sec-0164"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/table_n/CD009612StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/table_n/CD009612StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2016 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Nasal decongestants in monotherapy for the common cold</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#CD009612-cr-0002">Laura Deckx</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#CD009612-cr-0003">An IM De Sutter</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#CD009612-cr-0004">Linda Guo</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#CD009612-cr-0005">Nabiel A Mir</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information#CD009612-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Mieke L van Driel</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information/en#CD009612-sec-0171">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 17 October 2016 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD009612.pub2">https://doi.org/10.1002/14651858.CD009612.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD009612-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009612-abs-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009612-abs-0003">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009612-abs-0002">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD009612-abs-0001" lang="en"> <section id="CD009612-sec-0001"> <h3 class="title" id="CD009612-sec-0001">Background</h3> <p>Many treatments for the common cold exist and are sold over‐the‐counter. Nevertheless, evidence on the effectiveness and safety of nasal decongestants is limited. </p> </section> <section id="CD009612-sec-0002"> <h3 class="title" id="CD009612-sec-0002">Objectives</h3> <p>To assess the efficacy, and short‐ and long‐term safety, of nasal decongestants used in monotherapy to alleviate symptoms of the common cold in adults and children. </p> </section> <section id="CD009612-sec-0003"> <h3 class="title" id="CD009612-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6, June 2016), which contains the Cochrane Acute Respiratory Infections (ARI) Specialised Register, MEDLINE (1946 to July 2016), Embase (2010 to 15 July 2016), CINAHL (1981 to 15 July 2016), LILACS (1982 to July 2016), Web of Science (1955 to July 2016) and clinical trials registers. </p> </section> <section id="CD009612-sec-0004"> <h3 class="title" id="CD009612-sec-0004">Selection criteria</h3> <p>Randomised controlled trials (RCTs) and cluster‐RCTs investigating the effectiveness and adverse effects of nasal decongestants compared with placebo for treating the common cold in adults and children. We excluded quasi‐RCTs. </p> </section> <section id="CD009612-sec-0005"> <h3 class="title" id="CD009612-sec-0005">Data collection and analysis</h3> <p>Three review authors independently extracted and summarised data on subjective measures of nasal congestion, overall patient well‐being score, objective measures of nasal airway resistance, adverse effects and general recovery. One review author acted as arbiter in cases of disagreement. We categorised trials as single and multi‐dose and analysed data both separately and together. We also analysed studies using an oral or topical nasal decongestant separately and together. </p> </section> <section id="CD009612-sec-0006"> <h3 class="title" id="CD009612-sec-0006">Main results</h3> <p>We included 15 trials with 1838 participants. Fourteen studies included adult participants only (aged 18 years and over). In six studies the intervention was a single dose and in nine studies multiple doses were used. Nine studies used pseudoephedrine and three studies used oxymetazoline. Other decongestants included phenylpropanolamine, norephedrine and xylometazoline. Phenylpropanolamine (or norephedrine) is no longer available on the market therefore we did not include the results of these studies in the meta‐analyses. Eleven studies used oral decongestants; four studies used topical decongestants. </p> <p>Participants were included after contracting the common cold. The duration of symptoms differed among studies; in 10 studies participants had symptoms for less than three days, in three studies symptoms were present for less than five days, one study counted the number of colds over one year, and one study experimentally induced the common cold. In the single‐dose studies, the effectiveness of a nasal decongestant was measured on the same day, whereas the follow‐up in multi‐dose studies ranged between one and 10 days. </p> <p>Most studies were conducted in university settings (N = eight), six at a specific university common cold centre. Three studies were conducted at a university in collaboration with a hospital and two in a hospital only setting. In two studies the setting was unclear. </p> <p>There were large differences in the reporting of outcomes and the reporting of methods in most studies was limited. Therefore, we judged most studies to be at low or unclear risk of bias. Pooling was possible for a limited number of studies only; measures of effect are expressed as standardised mean differences (SMDs). A positive SMD represents an improvement in congestion. There is no defined minimal clinically important difference for measures of subjective improvement in nasal congestion, therefore we used the SMDs as a guide to assess whether an effect was small (0.2 to 0.49), moderate (0.5 to 0.79) or large (≥ 0.8). </p> <p>Single‐dose decongestant versus placebo: 10 studies compared a single dose of nasal decongestant with placebo and their effectiveness was tested between 15 minutes and 10 hours after dosing. Seven of 10 studies reported subjective symptom scores for nasal congestion; none reported overall patient well‐being. However, pooling was not possible due to the large diversity in the measurement and reporting of symptoms of congestion. Two studies recorded adverse events. Both studies used an oral decongestant and each of them showed that there was no statistical difference between the number of adverse events in the treatment group versus the placebo group. </p> <p>Multi‐dose decongestant versus placebo: nine studies compared multiple doses of nasal decongestants with placebo, but only five reported on the primary outcome, subjective symptom scores for nasal congestion. Only one study used a topical decongestant; none reported overall patient well‐being. Subjective measures of congestion were significantly better for the treatment group compared with placebo approximately three hours after the last dose (SMD 0.49, 95% confidence interval (CI) 0.07 to 0.92; P = 0.02; GRADE: low‐quality evidence). However, the SMD of 0.49 only indicates a small clinical effect. Pooling was based on two studies, one oral and one topical, therefore we were unable to assess the effects of oral and topical decongestants separately. Seven studies reported adverse events (six oral and one topical decongestant); meta‐analysis showed that there was no statistical difference between the number of adverse events in the treatment group (125 per 1000) compared to the placebo group (126 per 1000). The odds ratio (OR) for adverse events in the treatment group was 0.98 (95% CI 0.68 to 1.40; P = 0.90; GRADE: low‐quality evidence). The results remained the same when we only considered studies using an oral decongestant (OR 0.95, 95% CI 0.65 to 1.39; P = 0.80; GRADE: low‐quality evidence). </p> </section> <section id="CD009612-sec-0007"> <h3 class="title" id="CD009612-sec-0007">Authors' conclusions</h3> <p>We were unable to draw conclusions on the effectiveness of single‐dose nasal decongestants due to the limited evidence available. For multiple doses of nasal decongestants, the current evidence suggests that these may have a small positive effect on subjective measures of nasal congestion in adults with the common cold. However, the clinical relevance of this small effect is unknown and there is insufficient good‐quality evidence to draw any firm conclusions. Due to the small number of studies that used a topical nasal decongestant, we were also unable to draw conclusions on the effectiveness of oral versus topical decongestants. Nasal decongestants do not seem to increase the risk of adverse events in adults in the short term. The effectiveness and safety of nasal decongestants in children and the clinical relevance of their small effect in adults is yet to be determined. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD009612-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-abs-0012">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD009612-abs-0014">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD009612-abs-0010">Français</a> </li> <li class="section-language"> <a class="" href="full/hr#CD009612-abs-0009">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ms#CD009612-abs-0008">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/pl#CD009612-abs-0011">Polski</a> </li> <li class="section-language"> <a class="" href="full/ru#CD009612-abs-0007">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD009612-abs-0006">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD009612-abs-0005" lang="en"> <h3>Do nasal decongestants used alone relieve cold symptoms?</h3> <p><b>Review question</b> </p> <p>We wanted to find out if nasal decongestants used alone can ease nasal congestion symptoms in people with colds. </p> <p><b>Background</b> </p> <p>Colds, although not serious, are common illnesses responsible for many visits to family doctors and days lost from work and school. Cold symptoms include runny nose, sore throat and sneezing, and they can last up to two weeks. There is no cure for colds; treatments only ease the symptoms. Many people use over‐the‐counter medicines such as nasal decongestants to treat cold symptoms. However, there is little evidence that nasal decongestants actually work. We wanted to find out if nasal decongestants help ease congestion caused by colds. </p> <p>We considered studies that used a nasal decongestant as the only treatment for colds. We looked at subjective symptoms of congestion ‐ this means that symptoms and overall well‐being were self‐rated by patients. </p> <p><b>Search date</b> </p> <p>We searched for studies in July 2016.</p> <p><b>Study characteristics</b> </p> <p>We included 15 studies with 1838 participants; 14 included only adults aged 18 years or over. Six studies used a single‐dose nasal decongestant and measured the effects on the day it was administered. Nine studies used multiple doses and the effects were measured between one and 10 days after first administration. Eleven studies used tablets or syrup and four studies used nasal sprays. Eight studies were conducted at universities, three at universities in collaboration with hospitals and two in hospitals. The setting was unclear in two studies. </p> <p><b>Study funding sources</b> </p> <p>Nine studies were funded by drug manufacturers or agencies with commercial interests in the study results. Funding sources were unclear in six studies. </p> <p><b>Key results</b> </p> <p>We were unable to draw conclusions about single‐dose nasal decongestants. We found a small benefit in the relief of nasal congestion from multiple doses, but it was unclear if this was beneficial for patients. No studies reported overall patient well‐being. There was no difference in the numbers of adverse events between people who used a nasal decongestant and those who did not. We could not determine if there was a difference in effects between decongestant tablets and nasal sprays. The results relate to adults; there was no evidence on the effectiveness or safety of nasal decongestants for children. </p> <p><b>Quality of the evidence</b> </p> <p>We assessed the quality of the evidence for subjective cold symptoms as low for the multi‐dose studies ‐ there were few data and reporting was unclear. We also assessed the quality of the evidence for adverse events as low because of unclear reporting and because the estimates were not precise (there were wide confidence intervals ‐ a measure of statistical uncertainty). </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD009612-sec-0159" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-sec-0159">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-sec-0201">Español</a> </li> </nav> </div> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD009612-sec-0159"></div> <h3 class="title" id="CD009612-sec-0160">Implications for practice</h3> <section id="CD009612-sec-0160"> <p>The effectiveness of nasal decongestants in monotherapy is uncertain. There may be a small benefit on the subjective experience of nasal congestion after multiple doses of a nasal decongestant (low‐quality evidence). However, it is unclear if the small effect is clinically relevant. Due to the small number of studies that used a topical nasal decongestant, we were unable to draw conclusions on the effectiveness of oral versus topical decongestants. The incidence of mostly mild‐to‐moderate side effects was low. These results are applicable to adults only. Despite common colds being equally common in children, there is no evidence available on either effectiveness or safety in children. </p> </section> <h3 class="title" id="CD009612-sec-0161">Implications for research</h3> <section id="CD009612-sec-0161"> <p>Given the high consumption of nasal decongestants it was surprising that so little evidence is available. Questions about the effectiveness and safety in children remain unanswered. However, given the reports of serious adverse events in young children, further research in this group does not appear to be warranted or feasible (<a href="./references#CD009612-bbs2-0059" title="FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over‐the‐counter eye drops and nasal sprays. Federal Register 2012. http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm (accessed 3 November 2015). ">FDA 2012</a>). Some questions regarding the effectiveness and safety of nasal decongestants in adults also remain unanswered. More research is need to investigate the long‐term effects of multiple doses of nasal decongestants on tachyphylaxis or rhinitis medicamentosa and the differences between oral and topical decongestants need to be explored. </p> <p>We were unable to compare the effectiveness of different decongestants. For example, pseudoephedrine is often replaced by phenylephrine as a way to control methamphetamine abuse. However, as a decongestant, phenylephrine may not be as effective (<a href="./references#CD009612-bbs2-0054" title="EcclesR . Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. British Journal of Clinical Pharmacology2007;63(1):10‐4. [DOI: 10.1111/j.1365‐2125.2006.02833.x] ">Eccles 2007</a>). Despite phenylephrine being a common decongestant that is available over‐the‐counter, none of the included studies evaluated its effectiveness. Hence, more large‐scale, good‐quality randomised controlled trials evaluating the effectiveness of several nasal decongestants are needed. </p> <p>Furthermore, future research should seek to define a minimal clinically important difference for measures of subjective improvement in nasal congestion. As this was not available, we used a statistical approach to interpret our results. For example, a we regarded a standardised mean difference between 0.2 and 0.49 as a small effect. However, it remains unclear how this small statistical effect corresponds to clinical effect. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD009612-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD009612-sec-0029"></div> <div class="table" id="CD009612-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for single‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should a single dose of decongestant in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: single‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single‐dose decongestant</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>subjective symptom score ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540 (4 RCTs, oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); Phenylpropanolamine (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>overall patient well‐being ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome:<br/> all adverse events </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Two single‐dose trials reported adverse events (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Both used an oral decongestant. <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> (pseudoephedrine versus placebo) reported no adverse events in either the treatment or the placebo group; we did not include <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> (norephedrine versus placebo) results in the meta‐analysis because a cross‐over study design was used and several events per patient were reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (2 RCTs, oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Norephedrine (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>); Pseudoephedrine (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NAR:</b> nasal airway resistance; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD009612-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for multi‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should multiple doses of decongestant in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: multi‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> <p><b>Measure of effect:</b> we transformed results from all studies to ensure that higher scores represent better functioning. We standardised results using the standardised mean differences (SMD). As such differences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a large clinical effect. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with multi‐dose decongestant</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐7 to ‐35.79</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.49 standard units <b>better</b> in the treatment group (95% CI 0.07 to 0.92; <b>P value 0.02</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>); pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: overall patient well‐being</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.98<br/> (0.68 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1195<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); triprolidine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>); xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (89 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.95<br/> (0.65 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1134<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); triprolidine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b> <br/> (82 to 160) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events<br/> <b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of possible risk of bias; random sequence generation and allocation concealment was not clear in both studies. </p> <p><sup>2</sup>Downgraded because data came from only two studies. </p> <p><sup>3</sup>Downgraded because three studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), and the estimate had a wide confidence interval (imprecision). </p> <p><sup>4</sup>Downgraded because two studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), and the estimate had a wide confidence interval (imprecision). </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD009612-tbl-0003"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for all doses of nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should a decongestant (any dose) in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: single‐dose or multi‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> <p><b>Measure of effect:</b> we transformed results from all studies to ensure that higher scores represent better functioning. We standardised results using the standardised mean differences (SMD). As such differences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a large clinical effect. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with all doses of decongestants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐2.54 to ‐35.79</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.44 standard units <b>better</b> in the treatment group (95% CI 0.11 to 0.78; <b>P value 0.01</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐2.54 to ‐7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.33 standard units <b>better</b> in the treatment group (95% CI ‐0.11 to 0.77; <b>P value 0.14</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> <p><b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (AUC) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean AUC for the subjective symptom score ranged from 22 to ‐77.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.11 standard units <b>better</b> in the treatment group (95% CI ‐0.14 to 0.35; <b>P value 0.39</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies that used a topical decongestant reported the AUC for subjective symptoms of congestion </p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>overall patient well‐being</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome:<br/> All adverse events </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Only 2 single‐dose studies reported adverse events. One study reported no events (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, pseudoephedrine) and the other was excluded from meta‐analyses as this was a cross‐over study (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>, norephedrine). Combining single‐dose and multi‐dose studies would not change the results of the multi‐dose analyses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>AUC:</b> area under the curve; <b>NAR:</b> nasal airway resistance; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded because two studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> <p>²Downgraded because one study had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> <p>³Downgraded because data came from only two studies.</p> <p>⁴Downgraded because one study had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD009612-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-sec-0030">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-sec-0181">Español</a> </li> </nav> </div> </div> <section class="background" lang="en"> <div class="section-header" id="CD009612-sec-0030"></div> <section id="CD009612-sec-0031"> <h3 class="title" id="CD009612-sec-0031">Description of the condition</h3> <p>The common cold is viral in nature, afflicts individuals of all ages and often necessitates utilisation of over‐the‐counter and prescription medications, and complementary interventions (<a href="./references#CD009612-bbs2-0076" title="SimasekM , BlandinoD . Treatment of the common cold. American Family Physician2007;75(4):515‐20. ">Simasek 2007</a>). Often caused by the rhinovirus, people typically experience rhinorrhoea, sneezing, headache, nasal congestion, cough, fatigue and pharyngitis (<a href="./references#CD009612-bbs2-0053" title="EcclesR . Pathophysiology of nasal symptoms. American Journal of Rhinology2000;14(5):335‐8. ">Eccles 2000</a>). </p> <p>Despite the common cold not being a serious condition, it has a substantial impact in terms of time lost from work and school, as well as money spent on both prescription and over‐the‐counter medications (<a href="./references#CD009612-bbs2-0064" title="HeikkinnennT , JarvinenA . The common cold. Lancet2003;361(9351):51‐9. ">Heikkinnenn 2003</a>). In the USA, the common cold contributes to 22 million missed days from school and 20 million absences from work annually, including days missed due to caring for ill children (<a href="./references#CD009612-bbs2-0073" title="PappasD . The common cold in children. Available from www.uptodate.com2015. ">Pappas 2015</a>). In Australia, upper respiratory tract infections, nasal congestion, pharyngitis and cough constitute 11% of all consultations in general practice (<a href="./references#CD009612-bbs2-0061" title="FryJ , SandlerG . Common Diseases. Their Nature, Prevalence and Care. 5th Edition. Dordrecht: Kluwer Academic, 1993. ">Fry 1993</a>). In the USA, there are 25 million visits to the family physician annually due to the common cold and the total economic impact of the common cold reached around USD 40 billion annually (<a href="./references#CD009612-bbs2-0060" title="FendrickAM , MontoAS , NightengaleB , SarnesM . The economic burden of non‐influenza‐related viral respiratory tract infection in the United States. Archives of Internal Medicine2003;163(4):487–94. ">Fendrick 2003</a>). </p> </section> <section id="CD009612-sec-0032"> <h3 class="title" id="CD009612-sec-0032">Description of the intervention</h3> <p>Nasal congestion is one of the most uncomfortable symptoms experienced with the common cold (<a href="./references#CD009612-bbs2-0061" title="FryJ , SandlerG . Common Diseases. Their Nature, Prevalence and Care. 5th Edition. Dordrecht: Kluwer Academic, 1993. ">Fry 1993</a>). There is no cure for the common cold, therefore symptomatic therapy is the only treatment option. Nasal decongestants are widely utilised for symptomatic relief in both adults and children and can be administered in oral or topical form (<a href="./references#CD009612-bbs2-0051" title="DelMarC , GlasziouP . Upper respiratory tract infection. BMJ Clinical Evidence2003;10:1747‐56. ">Del Mar 2003</a>). </p> <p>Decongestants may contain pseudoephedrine, phenylephrine, oxymetazoline or xylometazoline. Nasal decongestants are available as tablets or nasal sprays or drops. They are mostly available over‐the‐counter without restrictions (<a href="./references#CD009612-bbs2-0055" title="EcclesR . Over the counter medicines for colds. In: EcclesR , WebberO editor(s). Common Cold. Basel: Birkhauser Verlag, 2009:23‐45. ">Eccles 2009</a>). It is recommended that they should not be given to children under the age of six years (<a href="./references#CD009612-bbs2-0072" title="NPSMedicinewise . Nasal decongestants. National Prescribing Service (http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants) (accessed 9 July 2016)2012. [http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants] ">NPS Medicinewise 2012</a>). Due to the risk of rebound congestion after stopping use of decongestants it is advised that people should not use a decongestant for longer than five days. Nasal decongestants mainly act locally but there may be systemic effects, such as hypertension. Other common side effects include headache, nausea, insomnia and dizziness (<a href="./references#CD009612-bbs2-0072" title="NPSMedicinewise . Nasal decongestants. National Prescribing Service (http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants) (accessed 9 July 2016)2012. [http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants] ">NPS Medicinewise 2012</a>). </p> <p>People taking topical nasal or ophthalmic decongestants quickly develop <a href="https://en.wikipedia.org/wiki/Tachyphylaxis" target="_blank">tachyphylaxis</a> (a rapid decrease in the response to a drug after repeated doses over a short period of time). Long‐term use is therefore not recommended, since the agents lose effectiveness after a few days. </p> <p>Previous reviews have considered the safety and efficacy of therapies for indications including seasonal and perennial allergic rhinitis, chronic rhinitis, common cold and influenza (<a href="./references#CD009612-bbs2-0052" title="DolanskyG , RiederM . What is the evidence for the safety and efficacy of over‐the‐counter cough and cold preparations for children younger than six years of age?. Journal of Paediatrics and Child Health2008;13(2):125‐7. ">Dolansky 2008</a>). Many marketed treatments for the common cold exist and they may consist of multiple active agents with claimed decongestant, anti‐secretory and anti‐cough actions. </p> <p>Heated, humidified air is one type of treatment intervention. The mechanism of action includes the liquefying of mucus if it is dry, thereby allowing it to be cleared more effectively. It also works by the heat of the steam killing the cold virus that may be present in the mucus. However, it is not routinely recommended as there is insufficient evidence for its use (<a href="./references#CD009612-bbs2-0077" title="SinghM , SinghM . Heated, humidified air for the common cold. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD001728.pub5] ">Singh 2013</a>). </p> <p>Corticosteroids are also used for the treatment of the common cold and have been recently reviewed (<a href="./references#CD009612-bbs2-0063" title="HaywardG , ThompsonMJ , PereraR , DelMarCB , GlasziouPP , HeneghanCJ . Corticosteroids for the common cold. Cochrane Database of Systematic Reviews2015, Issue 10. [DOI: 10.1002/14651858.CD008116.pub3] ">Hayward 2015</a>). Intranasal ipratropium bromide has been reviewed and was found to be effective in reducing rhinorrhoea but ineffective in reducing nasal congestion (<a href="./references#CD009612-bbs2-0045" title="AlBalawiZH , OthmanSS , AlFalehK . Intranasal ipratropium bromide for the common cold. Cochrane Database of Systematic Reviews2013, Issue 6. [DOI: 10.1002/14651858.CD008231.pub3] ">AlBalawi 2013</a>). </p> <p>A Cochrane Review of saline nasal irrigation has reported limited evidence of its efficacy in relieving symptoms of nasal secretion and nasal congestion in upper respiratory tract infections (<a href="./references#CD009612-bbs2-0067" title="KingD , MitchellB , WilliamsCP , SpurlingGKP . Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database of Systematic Reviews2015, Issue 4. [DOI: 10.1002/14651858.CD006821.pub3] ">King 2015</a>). </p> <p>Combination medications have also been studied. For overall recovery it has been reported that combinations of antihistamines, decongestants and analgesics have proven to be more effective compared to placebo (<a href="./references#CD009612-bbs2-0050" title="DeSutterAIM , vanDrielML , KumarAA , LesslarO , SkrtA . Oral antihistamine‐decongestant‐analgesic combinations for the common cold. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004976.pub3] ">De Sutter 2012</a>). There was only a modest effect of oral antihistamine‐decongestant combinations, oral decongestant‐analgesic combinations and oral antihistamine‐decongestant‐analgesic combinations on nasal congestion. Only oral analgesic combinations seemed to have no effect on the symptoms of nasal congestion. </p> <p>Since these medications for the common cold have already been previously researched, this review will focus on nasal decongestants. </p> </section> <section id="CD009612-sec-0033"> <h3 class="title" id="CD009612-sec-0033">How the intervention might work</h3> <p>Nasal decongestants are sympathomimetic amines that stimulate the alpha‐adrenergic receptors leading to vasoconstriction in the blood vessels supplying the upper respiratory tract structures (<a href="./references#CD009612-bbs2-0072" title="NPSMedicinewise . Nasal decongestants. National Prescribing Service (http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants) (accessed 9 July 2016)2012. [http://www.nps.org.au/medicines/ear‐nose‐mouth‐and‐throat/nasal‐decongestants] ">NPS Medicinewise 2012</a>; <a href="./references#CD009612-bbs2-0079" title="WickerA , LabruzzoB . Recommendations for the use of OTC cough and cold medications in children: decongestants. US Pharmacist2009;34(3):33‐6. ">Wicker 2009</a>). This results in a net reduction in oedema and nasal secretions and hence easier breathing. </p> </section> <section id="CD009612-sec-0034"> <h3 class="title" id="CD009612-sec-0034">Why it is important to do this review</h3> <p>This systematic review studied the efficacy and safety of nasal decongestants in people with the common cold. This review will provide evidence‐based guidance to clinicians and people with the common cold.  </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD009612-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-sec-0035">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-sec-0186">Español</a> </li> </nav> </div> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD009612-sec-0035"></div> <p>To assess the efficacy, and short‐ and long‐term safety, of nasal decongestants used in monotherapy to alleviate symptoms of the common cold in adults and children. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD009612-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-sec-0036">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-sec-0187">Español</a> </li> </nav> </div> </div> <section class="methods" lang="en"> <div class="section-header" id="CD009612-sec-0036"></div> <section id="CD009612-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD009612-sec-0038"> <h4 class="title">Types of studies</h4> <p>We included RCTs and cluster‐RCTs or randomised cross‐over studies comparing nasal decongestants with placebo. We excluded quasi‐RCTs. </p> </section> <section id="CD009612-sec-0039"> <h4 class="title">Types of participants</h4> <p>Adults and children of all ages and either gender with the common cold, characterised by defined symptoms of an upper respiratory tract infection (URTI), were eligible for inclusion. We included participants who had symptoms for no more than seven days prior to the start of the study. We excluded studies where another upper respiratory condition (such as influenza, sinusitis or rhinitis) had been diagnosed. </p> </section> <section id="CD009612-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Oral or topical nasal decongestants versus placebo (oral or spray, as appropriate).</p> <p>We included trials using topical and oral nasal decongestants administered as aqueous spray, drops, dry powder, tablets or capsules. We focused on nasal decongestants only, which work by stimulating the alpha‐adrenergic receptors in upper respiratory tract blood vessels, leading to vasoconstriction (<a href="./references#CD009612-bbs2-0079" title="WickerA , LabruzzoB . Recommendations for the use of OTC cough and cold medications in children: decongestants. US Pharmacist2009;34(3):33‐6. ">Wicker 2009</a>). We excluded studies reporting combined interventions such as warm humidified air, steam, aromatic vapours, inhaled corticosteroids and interventions using menthol. </p> </section> <section id="CD009612-sec-0041"> <h4 class="title">Types of outcome measures</h4> <section id="CD009612-sec-0042"> <h5 class="title">Primary outcomes</h5> <p> <ol id="CD009612-list-0001"> <li> <p>Subjective symptom scores for nasal congestion (self‐reported scores of congestion).</p> </li> <li> <p>Overall patient well‐being score (self‐reported).</p> </li> </ol> </p> </section> <section id="CD009612-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ol id="CD009612-list-0002"> <li> <p>Objective measures of nasal airway resistance (NAR).</p> </li> <li> <p>Adverse events (for example, dry mucous membranes, rebound congestion).</p> </li> <li> <p>Complications (for example, sinusitis, otitis media, lower respiratory tract infections).</p> </li> <li> <p>Time to full recovery.</p> </li> <li> <p>Time to return to school or work.</p> </li> </ol> </p> </section> </section> </section> <section id="CD009612-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD009612-sec-0045"> <h4 class="title">Electronic searches</h4> <p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 6 June, 2016), which contains the Cochrane Acute Respiratory Infections (ARI) Specialised Register, MEDLINE (1946 to July 15 July 2016), Embase (2010 to 15 July 2016), CINAHL (1981 to 15 July 2016), LILACS (1982 to 15 July 2016) and Web of Science (1955 to 15 July 2016). </p> <p>We used the search strategy as outlined in <a href="./appendices#CD009612-sec-0165">Appendix 1</a> to search MEDLINE and CENTRAL. We combined the MEDLINE search strategy with the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (<a href="./references#CD009612-bbs2-0069" title="LefebvreC , ManheimerE , GlanvilleJ (editors) . Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Lefebvre 2011</a>; <a href="./appendices#CD009612-sec-0165">Appendix 1</a>). We adapted the search strategy to search Embase (<a href="./appendices#CD009612-sec-0166">Appendix 2</a>), CINAHL (<a href="./appendices#CD009612-sec-0167">Appendix 3</a>), LILACS (<a href="./appendices#CD009612-sec-0168">Appendix 4</a>) and Web of Science (<a href="./appendices#CD009612-sec-0169">Appendix 5</a>). There were no language or publication restrictions. </p> </section> <section id="CD009612-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We searched <a href="http://www.clinicaltrials.gov" target="_blank">www.clinicaltrials.gov</a> and <a href="http://www.anzctr.org.au/" target="_blank">www.anzctr.org.au</a> to identify completed and ongoing trials (July 2016). We reviewed reference lists and contacted researchers in the field to identify further relevant studies. We contacted manufacturers of nasal decongestants for unpublished studies. </p> </section> </section> <section id="CD009612-sec-0047"> <h3 class="title" id="CD009612-sec-0047">Data collection and analysis</h3> <p>This review is based on our published protocol (<a href="./references#CD009612-bbs2-0080" title="Ta'iSH , FergusonKAM , SinghHK , SharmaAN , KumarS , vanDrielML , et al. Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD009612] ">Ta'i 2012</a>). </p> <section id="CD009612-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (LD, NM) independently reviewed and applied the inclusion and exclusion criteria to the titles and abstracts identified by the search. We retrieved the full text if there was insufficient information in the titles or abstracts to exclude a study. Three review authors (LD, NM, LG) reviewed full‐text articles, ensuring that two review authors independently judged each article. We consulted a fourth review author (MLvD) if there was any discrepancy between the two authors and the issue was resolved by discussion. The review authors were not blinded to information about the article, such as the journal title, the authors of the articles or the results. </p> <p>We recorded the selection process in sufficient detail to complete a PRISMA flow diagram (<a href="#CD009612-fig-0001">Figure 1</a>; <a href="./references#CD009612-bbs2-0071" title="MoherD , LiberatiA , TetzlaffJ , AltmanDG , The PRISMA Group. Preferred reporting items for systematic reviews and meta‐analyses: The PRISMA Statement. BMJ2009;339:2535. ">Moher 2009</a>) and <a href="./references#CD009612-sec-0178" title="">Characteristics of excluded studies</a> table. We did not impose any language restrictions. </p> <div class="figure" id="CD009612-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram" data-id="CD009612-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> </div> </section> <section id="CD009612-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>Three review authors (LD, NM, LG) independently extracted data from all included articles using pre‐designed data extraction forms. A fourth author (MLvD) assisted in reaching a consensus if data entries differed. We extracted the following data: </p> <p> <ul id="CD009612-list-0003"> <li> <p>First author, publication year, journal.</p> </li> <li> <p>Number, age and gender distribution of the patients included in the trial.</p> </li> <li> <p>Case definitions (symptoms and measurements).</p> </li> <li> <p>Type, dosage, duration and route of administration of nasal decongestant.</p> </li> <li> <p>Results (primary and secondary outcomes).</p> </li> </ul> </p> <p>If a paper did not provide sufficient information about either study details or results, we contacted the authors where possible. </p> </section> <section id="CD009612-sec-0050"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Three review authors (LD, NM, LG) independently assessed risk of bias. We resolved disagreements by discussion with an arbiter (MLvD). We assessed: </p> <p> <ul id="CD009612-list-0004"> <li> <p>random sequence generation;</p> </li> <li> <p>allocation concealment;</p> </li> <li> <p>blinding of participants and personnel (if relevant);</p> </li> <li> <p>blinding of outcome assessors;</p> </li> <li> <p>incomplete outcome data;</p> </li> <li> <p>dropout/selective outcome reporting; and</p> </li> <li> <p>other potential sources of bias.</p> </li> </ul> </p> <p>We judged each potential source of bias as high, low or unclear and provided a quote from the study report together with a justification for our judgement in 'Risk of bias' tables. We summarised the risk of bias judgements across different studies for each of the domains listed. We reported the risk of bias using the 'Risk of bias' tool from the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> </section> <section id="CD009612-sec-0051"> <h4 class="title">Measures of treatment effect</h4> <p>We reported continuous data as the standardised mean difference (SMD) because subjective and objective measures of congestion were measured on different scales. The SMD adjusts for the differences in measurement scales and enables data from different scoring systems to be pooled; it is the absolute mean difference divided by the standard deviation (SD). Dichotomous outcomes were reported as odds ratios (ORs). SMDs and ORs were generated by RevMan software (<a href="./references#CD009612-bbs2-0074" title="The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">RevMan 2014</a>). We calculated 95% confidence intervals (CIs) for each estimate. </p> </section> <section id="CD009612-sec-0052"> <h4 class="title">Unit of analysis issues</h4> <p>We analysed the outcomes of the individual participants of each trial. If the unit of randomisation was not the same as the level of analysis (i.e. the individual participants), such as in cluster‐RCTs, we planned to make adjustments by taking into account the impact of clustering as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>If a trial included more than one treatment arm that was similar (such as different doses of the same nasal decongestant), we combined data from the treatment arms that were similar and compared this group to the control group, as recommended in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i>, section 7.7.3.8 and Table 7.7a (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>For studies using a cross‐over design, we reported results separately and did not include them in the meta‐analysis. </p> </section> <section id="CD009612-sec-0053"> <h4 class="title">Dealing with missing data</h4> <p>We were unable to obtain additional data from study authors (many studies were quite old and authors could not be contacted). Therefore, where possible, we compared studies that used an intention‐to‐treat (ITT) analysis (assuming that all missing data represented unsuccessful outcomes) to those not reporting ITT analysis (on‐treatment analysis) in a sensitivity analysis to assess the potential impact of missing data on the overall effect of treatment. </p> </section> <section id="CD009612-sec-0054"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity in two ways. First, we explored the presence of heterogeneity at face value by comparing population groups, interventions or outcomes across studies. In the case of clear face value heterogeneity we reported the outcomes of the studies as in a systematic review but we did not pool the results. If there was no obvious heterogeneity we used statistical tests such as the Cochrane Chi² (Q) test and the I² statistic to determine the presence and level of statistical heterogeneity for each outcome (<a href="./references#CD009612-bbs2-0065" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). We considered an I² statistic of 60% or more to represent important heterogeneity. Where possible we explored the causes of statistical heterogeneity using subgroup and sensitivity analyses. We specified a priori that we would not carry out a meta‐analysis if heterogeneity was greater than 90% and there was too much variation in the results, particularly inconsistency in the direction of the effect. </p> </section> <section id="CD009612-sec-0055"> <h4 class="title">Assessment of reporting biases</h4> <p>We did not identify more than 10 studies for any of the outcome measures. Therefore, it was not possible to assess reporting bias using funnel plots as described in section 10.4.3 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0078" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> </section> <section id="CD009612-sec-0056"> <h4 class="title">Data synthesis</h4> <p>We analysed single‐dose and multi‐dose studies separately as well as combined. Clinically, we expect that a single or multi‐dose of nasal decongestant would have a similar effect, although it may not be as long lasting in the case of a single dose. Therefore, we combined measurements of single and multi‐dose studies for up to three hours after dosing. </p> <p>We included results from studies that met the inclusion criteria and reported the selected outcomes in the meta‐analysis. We calculated the summary weighted OR and 95% CI for dichotomous secondary outcomes using the inverse of the variance of each study result for weighting. We standardised the results of the studies to a uniform scale when looking at continuous outcomes. In this case, we used the SMD to express the size of the intervention effect in each study relative to the variability observed in that study. We planned to calculate the number needed to treat to benefit (NNTB) for an additional beneficial outcome using the summary OR and the average control event rate described in the relevant studies. However, this was not possible because all studies assessed improvement in nasal congestion on a continuous scale. We performed fixed‐effect meta‐analyses and random‐effects meta‐analyses and compared the two models. We reported any differences between the models, but throughout all analyses we used a random‐effects model for final reporting. </p> <p>There is no defined minimal clinically important difference for measures of subjective improvement in nasal congestion, therefore we used the SMDs as a guide. However, SMDs are difficult to interpret and several options are available for re‐expressing SMDs: every method has its benefits and pitfalls. For this review we decided to use rules of thumb for effect sizes as a guide: 0.2 to 0.49 represents a small effect, 0.5 to 0.79 a moderate effect and ≥ 0.8 a large effect, as described in section 12.6.2 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0078" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). </p> <section id="CD009612-sec-0057"> <h5 class="title">GRADE and 'Summary of findings' tables</h5> <p>We created 'Summary of findings' tables using the following outcomes: subjective symptom scores for nasal congestion, overall patient well‐being and adverse events. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness and publication bias) to assess the quality of the body of evidence as it relates to the studies that contributed data to the meta‐analyses for the prespecified outcomes (<a href="./references#CD009612-bbs2-0049" title="AtkinsD , BestD , BrissPA , EcclesM , Falck‐YtterY , FlottorpS , et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ2004;328(7454):1490. ">Atkins 2004</a>). We included the following comparisons: single‐dose decongestant versus placebo, multi‐dose decongestant versus placebo and all doses versus placebo. We used the methods and recommendations described in Section 8.5 and Chapter 12 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>), using the GRADEproGDT software (<a href="./references#CD009612-bbs2-0062" title="McMaster University (developed by Evidence Prime, Inc.). GRADEproGDT: GRADEpro Guideline Development Tool [www.guidelinedevelopment.org]. Hamilton: McMaster University (developed by Evidence Prime, Inc.), 2015. ">GRADEproGDT 2015</a>). We justified all decisions to downgrade or upgrade the quality of studies using footnotes, and we made comments to aid readers' understanding of the review where necessary. </p> </section> </section> <section id="CD009612-sec-0058"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We decided a priori that, if sufficient data were available, we would conduct the following subgroup analyses to explore differential treatment effects. </p> <p> <ul id="CD009612-list-0005"> <li> <p>Children (aged up to 12 years) versus others (aged over 12 years).</p> </li> <li> <p>Topical versus oral nasal decongestants.</p> </li> </ul> </p> </section> <section id="CD009612-sec-0059"> <h4 class="title">Sensitivity analysis</h4> <p>We decided a priori to perform sensitivity analyses to assess the impact of heterogeneity on the overall outcome (pooled estimate) of the meta‐analysis. We did this by gradually removing single trials to investigate the extent to which they contributed to heterogeneity. We also used sensitivity analyses to assess the impact of risk of bias on the overall pooled estimate by first pooling the studies with low risk of bias and then gradually adding the studies assessed as having a high risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD009612-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD009612-sec-0060"></div> <section id="CD009612-sec-0061"> <h3 class="title">Description of studies</h3> <p>All results are based on published data only. More information about the studies is presented in <a href="./references#CD009612-sec-0177" title="">Characteristics of included studies</a>, <a href="./references#CD009612-sec-0178" title="">Characteristics of excluded studies</a>, <a href="./references#CD009612-sec-0179" title="">Characteristics of studies awaiting classification</a> and <a href="./references#CD009612-sec-0180" title="">Characteristics of ongoing studies</a>. </p> <section id="CD009612-sec-0062"> <h4 class="title">Results of the search</h4> <p>We retrieved 888 records with duplicates removed from the searches of the electronic databases (CENTRAL 285, MEDLINE 364, Embase 427, CINAHL 70, LILACS 3 and Web of Science 216). Based on screening of titles and abstracts, we excluded 847 records; we assessed the full text of the remaining 41 articles for eligibility (<a href="#CD009612-fig-0001">Figure 1</a>). We excluded 25 studies based on the full text. Two studies have not yet been classified (<a href="./references#CD009612-bbs2-0041" title="NCT00452270 . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of xylometazoline in subjects with a common cold. https://clinicaltrials.gov/ct2/show/NCT00452270 (accessed 6 October 2015). ">NCT00452270</a>; <a href="./references#CD009612-bbs2-0042" title="NCT01062360 . A pivotal, placebo controlled, phase III study to compare efficacy and tolerability of a fixed combination, containing 500 mg ASA and 30 mg pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion. https://clinicaltrials.gov/ct2/show/NCT01062360 (accessed 6 October 2015). ">NCT01062360</a>), and two studies are ongoing (<a href="./references#CD009612-bbs2-0043" title="EUCTR2006‐006690‐25‐GB . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of otrivin F2 in subjects with a common cold ‐ a study to evaluate the decongestant effect of Otrivin F2. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐006690‐25/GB (accessed 6 October 2015). ">EUCTR2006‐006690‐25‐GB</a>; <a href="./references#CD009612-bbs2-0044" title="NCT01744106 . A multicenter study of pseudoephedrine for the temporary relief of nasal congestion in children with the common cold. https://clinicaltrials.gov/ct2/show/NCT01744106 (accessed 6 October 2015). ">NCT01744106</a>). The reasons for the exclusion of the 25 excluded studies are shown in <a href="./references#CD009612-sec-0178" title="">Characteristics of excluded studies</a> table. </p> </section> <section id="CD009612-sec-0063"> <h4 class="title">Included studies</h4> <p>We included 16 references to 15 RCTs (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> was published as a full paper as well as an abstract). The interventions consisted of single doses (N = 6) (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), and multiple doses (N = 9) of nasal decongestants (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). Some interventions included a treatment arm with combination therapy (e.g. pseudoephedrine plus paracetamol). However, in this review we focused on the effectiveness of nasal decongestants only. Therefore, we did not include the treatment arms that considered combination therapy. </p> <section id="CD009612-sec-0064"> <h5 class="title">Design</h5> <p>The included trials were randomised and placebo‐controlled. With the exception of one (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), all trials were double‐blinded. Fourteen of the RCTs were parallel‐group studies, and only one cross‐over design trial was included (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>). </p> </section> <section id="CD009612-sec-0065"> <h5 class="title">Sample sizes</h5> <p>The included trials involved 2596 participants, including all treatment groups, as well as those receiving combination therapy. When participants receiving combination therapy or other drugs (e.g. paracetamol only) were excluded, the total number of participants was 1838. </p> </section> <section id="CD009612-sec-0066"> <h5 class="title">Setting</h5> <p>The studies were conducted in the United States (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), United Kingdom (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), Sweden (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>), Denmark (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>), Germany (<a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>) and Australia (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Six studies from the UK were conducted at the Common Cold Centre of Cardiff University (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), and the three Australian studies were conducted at the University of Adelaide and the Royal Adelaide Hospital (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). The remaining studies were conducted in a university (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), or hospital setting (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>). The setting was unclear in two studies (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). </p> </section> <section id="CD009612-sec-0067"> <h5 class="title">Participants</h5> <p>The participants of six trials were recruited from the community via poster advertisements (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), one of which only advertised in a students’ magazine (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>). Two trials recruited males undergoing military training (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>), and staff from a charity foundation (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>). Recruitment procedures were unclear in seven trials (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> <p>With one exception, all studies included adult participants only (<a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). The cut‐off in 10 studies was 18 years of age (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); five studies did not provide an age range (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). In most trials the mean age was under 25 years (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); mean ages were 26 years and 30 years respectively in <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> and <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>. Six trials did not provide the mean age (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> was the only study to include younger people (participants had to be older than 12 years; however, the mean age of included participants was not provided. </p> <p>Thirteen studies clearly defined cut‐offs for the time since onset of the common cold (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Ten studies used cut‐off durations of less than three days (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>); three studies used cut‐offs of less than five days (<a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). One study counted the total number of colds over the period of a year and did not specify the duration between onset of symptoms and enrolment in the study (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>); another experimentally induced the common cold via intranasal rhinovirus challenge (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). The duration of follow‐up varied from one to 10 days. All six single‐dose studies measured the effectiveness of a nasal decongestant on the same day and, thus, had a follow‐up of one day (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). The remaining multi‐dose studies had follow‐up of one (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), three (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>), four (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), or 10 days (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). </p> <p>Ten included RCTs clearly defined the inclusion criteria for cold symptoms (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Six studies used an objective criterion (e.g. nasal obstruction as measured by posterior rhinomanometry) (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), whereas four trials used a certain number of symptoms or a subjective measure as cut‐off (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>). <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>, <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>, <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> and <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> did not clearly describe a diagnostic criterion. </p> </section> <section id="CD009612-sec-0068"> <h5 class="title">Interventions</h5> <p>Nine trials used pseudoephedrine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), and three investigated oxymetazoline (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). Others used xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>), phenylpropanolamine (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>), or norephedrine (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>). However, in 2000, the US Food and Drugs Administration (FDA) issued a public health advisory recommending that phenylpropanolamine (also known as norephedrine) should not be considered safe for over‐the‐counter use and asked the drug manufacturers to voluntarily discontinue marketing products containing phenylpropanolamine (<a href="./references#CD009612-bbs2-0057" title="FDA Public Health Advisory: Safety of Phenylpropanolamine. Federal Register 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm052236.htm (accessed 22 April 2016). ">FDA 2000</a>). As a consequence, phenylpropanolamine is no longer available as a decongestant in most countries. Therefore, we excluded <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> and <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> from the meta‐analyses. </p> <p>Seven studies that used pseudoephedrine generally administered multiple doses (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), and all used oral tablets, with the exception of <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a> and <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> who used granule sachets and oral capsules respectively. Of the remaining six studies that did not use pseudoephedrine, four used a single dose of medication (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>). Only four studies used a topical decongestant (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). See <a href="#CD009612-tbl-0004">Table 1</a> for an overview. </p> <div class="table" id="CD009612-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reference</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Single/multi‐dose study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Decongestant</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mode of administration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because insufficient details were provided to standardise the results </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because a cross‐over design was used and because norephedrine (phenylpropanolamine) is no longer available on the market </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenylpropanolamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because phenylpropanolamine is no longer available on the market </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xylometazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Max 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> </div> </section> <section id="CD009612-sec-0069"> <h5 class="title">Outcomes</h5> <p>Seven RCTs reported nasal airway resistance (NAR) as the primary outcome (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Two studies reported nasal airway conductance (NAC) as the primary outcome, which is the inverse of NAR (<a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>). The benefit of NAC over NAR is that with NAC it is possible to collect data from participants with total nasal obstruction (= zero conductance), whereas resistance would tend towards infinity. Other primary outcome measures were severity of subjective symptoms (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), nasal nitric oxide levels (<a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>), nasal volume (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>), minimum and maximum airflow (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), and numbers of days until full recovery (<a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). NAR was measured by a rhinomanometry test, which assesses nasal airflow obstructions by measuring pressure and flow during normal inspiration and expiration. Most studies used posterior rhinomanometry, where both nostrils are measured simultaneously (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Only one study used anterior rhinomanometry only, which measures one nostril at a time (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>). <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> used both posterior and anterior rhinomanometry, and <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a> used posterior rhinomanometry, but each nostril was assessed separately by alternately occluding each nostril with surgical tape. </p> <p>Subjective symptom scores for congestion were often reported as secondary outcome measurements (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>). In total, 12 of 15 studies reported subjective symptom scores for congestion (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Subjective symptom scores were either reported on a Likert scale of severity (ranging from 4 to 7 points) (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), or on a 100 mm visual analogue scale (VAS) where 0 mm represented complete nasal patency and 100 mm represented complete nasal blockage (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). </p> <p>Two studies also measured the time to onset of subjective relief (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>), but other preselected outcomes such as overall well‐being, complications, time to full recovery and time to return to school or work were not reported. Most included studies also reported the frequency of adverse effects (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> stated that adverse events were measured but these were not reported. </p> </section> <section id="CD009612-sec-0070"> <h5 class="title">Funding</h5> <p>Nine RCTs clearly stated funding sources. These were usually commercial entities. Funding involved pharmaceutical companies such as Pfizer Consumer HealthCare group (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>), Procter and Gamble Company (<a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), Bayer HealthCare LLC (<a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>), GlaxoSmithKline (<a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>), Novartis (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>), H. Lundbeck and Co (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>), Richardson‐Vicks and the Aspirin Foundation of America (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). Five trials did not indicate sources of funding (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>); the source of funding for <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> was not clear, but the treatment medication was provided by Pfizer Consumer HealthCare Group. </p> </section> </section> <section id="CD009612-sec-0071"> <h4 class="title">Excluded studies</h4> <p>We excluded 25 trials. Ten trials were excluded because the study participants’ symptoms of nasal congestion or obstruction were for reasons other than the common cold (e.g. allergic rhinitis) (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0019" title="AsheGJ . Oral medications in nasal decongestion. A study among industrial workers. Industrial Medicine and Surgery1968;37(3):212‐4. ">Ashe 1968</a>; <a href="./references#CD009612-bbs2-0020" title="BaileyBJ . Clinical evaluation of a topical nasal decongestant ‐ oxymetazoline. Eye, Ear, Nose &amp; Throat Monthly1969;48(9):512‐5. ">Bailey 1969</a>; <a href="./references#CD009612-bbs2-0021" title="BendeM , AnderssonKE , JohanssonCJ , SjögrenC , SvenssonG . Dose‐response relationship of a topical nasal decongestant: phenylpropanolamine. Acta Oto‐Laryngologica1984;98(5‐6):543‐7. ">Bende 1984</a>; <a href="./references#CD009612-bbs2-0022" title="BendeM . Contralateral effects of unilateral nasal decongestion. Acta Oto‐Laryngologica1985;99(5‐6):637‐40. ">Bende 1985</a>; <a href="./references#CD009612-bbs2-0024" title="CastellanoF , MautoneG . Decongestant activity of a new formulation of xylometazoline nasal spray: a double‐blind, randomized versus placebo and reference drugs controlled, dose‐effect study. Drugs Under Experimental &amp; Clinical Research2002;28(1):27‐35. ">Castellano 2002</a>; <a href="./references#CD009612-bbs2-0026" title="ConnellJT . Effectiveness of topical nasal decongestants. Annals of Allergy1969;27(11):541‐6. ">Connell 1969</a>; <a href="./references#CD009612-bbs2-0034" title="PritchardS , GloverM , GuthrieG , BrumJ , RamseyD , KapplerG , et al. Effectiveness of 0.05% oxymetazoline (Vicks Sinex Micromist®) nasal spray in the treatment of objective nasal congestion demonstrated to 12 h post‐administration by magnetic resonance imaging. Pulmonary Pharmacology and Therapeutics2014;27(1):121‐6. ">Pritchard 2014</a>; <a href="./references#CD009612-bbs2-0037" title="TzachevCT , MandajievaM , MinkovEH , PopovTA . Comparison of the clinical efficacy of standard and mucoadhesive‐based nasal decongestants. British Journal of Clinical Pharmacology2002;53(1):107‐9. ">Tzachev 2002</a>; <a href="./references#CD009612-bbs2-0040" title="ZumpftCW . Double‐blind comparison of metizoline hydrochloride (Ellsyl) and phenylephrine in allergic and vasomotor rhinitis. Current Therapeutic Research1975;17(1):40‐6. ">Zumpft 1975</a>). We excluded five studies due to lack of randomisation (<a href="./references#CD009612-bbs2-0017" title="AndersonHA . Clinical trial of tetrahydrozoline pediatric nasal decongestant. Antibiotic Medicine &amp; Clinical Therapy1956;3(3):199‐201. ">Anderson 1956</a>; <a href="./references#CD009612-bbs2-0018" title="Anonymous . Evaluation of a new oxymetazoline preparation in the treatment of nasal congestion. A multicentre trial. Practitioner1975;214(1283):685‐8. ">Anonymous 1975</a>; <a href="./references#CD009612-bbs2-0031" title="KatranaNJ . Clinical trial of tyzine, a new nasal decongestant. Illinois Medical Journal1956;110(1):19‐21. ">Katrana 1956</a>; <a href="./references#CD009612-bbs2-0032" title="McElhenneyTR , GraterWC , PfeifferGO , SandersSH , McGovernJP , WeisbergJ . A comparative evaluation of four oral nasal decongestants. Current Therapeutic Research1966;8(6):291‐8. ">McElhenney 1966</a>; <a href="./references#CD009612-bbs2-0036" title="SmithA , SturgessW , RichN , BriceC , CollisonC , BaileyJ , et al. The effects of idazoxan on reaction times, eye movements and the mood of healthy volunteers and patients with upper respiratory tract illnesses. Journal of Psychopharmacology1999;13(2):148‐51. ">Smith 1999</a>), three due to lack of a placebo control group (<a href="./references#CD009612-bbs2-0028" title="DornM , HofmannW , KnickE . Tolerance and effectiveness of oxymetazoline and xylometazoline in treatment of acute rhinitis [Verträglichkeit und Wirksamkeit von Oxymetazolin* und Xylometazolin bei der Behandlung der akuten Rhinitis]. HNO2003;51(10):794‐9. ">Dorn 2003</a>; <a href="./references#CD009612-bbs2-0029" title="FoxSL . The use of oral decongestants in the management of diverse types of nasal congestion. Current Therapeutic Research1967;9(5):247‐52. ">Fox 1967</a>; <a href="./references#CD009612-bbs2-0033" title="MeurmanOH . A controlled clinical comparison of nasal decongestants in acute rhinitis. Journal of International Medical Research1975;3(5):356‐62. ">Meurman 1975</a>), and four because only combination therapy was used or reported (<a href="./references#CD009612-bbs2-0025" title="CohenBM . Physiologic and subjective comparisons of 2 oral sustained‐release nasal decongestant combinations and placebo in patients with common colds. Current Therapeutic Research1977;22(4):522‐8. ">Cohen 1977</a>; <a href="./references#CD009612-bbs2-0027" title="DePaula NevesF . Clinical trial of a drug combination (JJ‐4482) used for the treatment of catarrhal inflammations of the upper respiratory tract [Ensaio clinico com uma associacao medicamentosa (JJ‐4482) destinada ao tratamento das inflamacoes catarrais das vias aereas superiores]. Revista Brasileira de Medicina1966;23(12):878‐80. ">De Paula Neves 1966</a>; <a href="./references#CD009612-bbs2-0035" title="RumiantsevAG , AldoninaVV , Il'inaTP , SnitarenkoVI , BiriuchinskaiaIG , ShevaldinaTV . A trial of the use of the prolonged‐action preparation Koldakt from the Natko firm for treating upper respiratory tract diseases in polyclinics [Opyt primeneniia preparata prolongirovannogo deistviia &quot;Koldakt&quot; firmy &quot;Natko&quot; dlia lecheniia zabolevanii verkhnikh dykhatel'nykh putei v poliklinicheskikh usloviiakh]. Terapevticheskii Arkhiv1993;65(11):70, 72. ">Rumiantsev 1993</a>; <a href="./references#CD009612-bbs2-0038" title="WeisbergJ , BreslowI . The evaluation of a nasal decongestant preparation. Archives of Otolaryngology1966;83(5):477‐9. ">Weisberg 1966</a>). Other reasons included symptom duration of more than six months (<a href="./references#CD009612-bbs2-0023" title="BromsP , MalmL . Oral vasoconstrictors in perennial non‐allergic rhinitis. Allergy1982;37(2):67‐74. ">Broms 1982</a>), and not measuring any of the predefined outcomes (<a href="./references#CD009612-bbs2-0030" title="HummelT , RothbauerC , PauliE , KobalG . Effects of the nasal decongestant oxymetazoline on human olfactory and intranasal trigeminal function in acute rhinitis. European Journal of Clinical Pharmacology1998;54(7):521‐8. ">Hummel 1998</a>; <a href="./references#CD009612-bbs2-0039" title="WintherB , BrofeldtS , BorumP , PedersenM , MygindN . Lack of effect on nasal discharge from a vasoconstrictor spray in common cold. European Journal of Respiratory Diseases Supplement1983;128(Pt 2):447‐8. ">Winther 1983</a>). </p> <section id="CD009612-sec-0072"> <h5 class="title">Ongoing studies</h5> <p>We identified two ongoing trials. Both are commercially funded, double‐blind RCTs involving participants with the common cold and use of nasal decongestants. <a href="./references#CD009612-bbs2-0043" title="EUCTR2006‐006690‐25‐GB . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of otrivin F2 in subjects with a common cold ‐ a study to evaluate the decongestant effect of Otrivin F2. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐006690‐25/GB (accessed 6 October 2015). ">EUCTR2006‐006690‐25‐GB</a> is a parallel‐group study entered into the European clinical trials register in 2007. This study investigates the changes in nasal conductance in participants aged over 18 years with the decongestant xylometazoline. No information on the expected end date of this study was provided. <a href="./references#CD009612-bbs2-0044" title="NCT01744106 . A multicenter study of pseudoephedrine for the temporary relief of nasal congestion in children with the common cold. https://clinicaltrials.gov/ct2/show/NCT01744106 (accessed 6 October 2015). ">NCT01744106</a> is a multicentre study that began in November 2012 involving the response of nasal congestion severity in children between the ages of six and 11 years to the decongestant pseudoephedrine. The expected completion date was April 2015, however, this was changed to May 2016. </p> </section> <section id="CD009612-sec-0073"> <h5 class="title">Studies awaiting classification</h5> <p>Two studies are awaiting classification (<a href="./references#CD009612-bbs2-0041" title="NCT00452270 . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of xylometazoline in subjects with a common cold. https://clinicaltrials.gov/ct2/show/NCT00452270 (accessed 6 October 2015). ">NCT00452270</a>; <a href="./references#CD009612-bbs2-0042" title="NCT01062360 . A pivotal, placebo controlled, phase III study to compare efficacy and tolerability of a fixed combination, containing 500 mg ASA and 30 mg pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion. https://clinicaltrials.gov/ct2/show/NCT01062360 (accessed 6 October 2015). ">NCT01062360</a>). Both are commercially funded, double‐blind RCTs involving the response of nasal congestion in participants aged over 18 years with the common cold to nasal decongestants (xylometazoline and pseudoephedrine). Although both studies were completed before 2011, we were unable to find their published results. </p> </section> </section> </section> <section id="CD009612-sec-0074"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed all included trials using the six specific domains detailed in the <i>Cochrane Handbook of Systematic Review of Interventions</i> 'Risk of bias' tool (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). The results of this assessment are shown for each study in <a href="#CD009612-fig-0002">Figure 2</a> and summarised in <a href="#CD009612-fig-0003">Figure 3</a>. Details of the included studies are presented in <a href="./references#CD009612-sec-0177" title="">Characteristics of included studies</a>. Overall, most judgements were unclear due to lack of detail provided in the trials reports. For example, clear and detailed descriptions of the methods of sequence generation, allocation concealment and blinding were often missing. Many studies also had pharmaceutical company funding of unknown significance. We deemed only one study to be high risk in any of the six domains (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>); this was because the study was not blinded and therefore assessed as high risk in both blinding domains. </p> <div class="figure" id="CD009612-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages for all included studies" data-id="CD009612-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages for all included studies </p> </div> </div> </div> <div class="figure" id="CD009612-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009612-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> </div> <section id="CD009612-sec-0075"> <h4 class="title">Allocation</h4> <section id="CD009612-sec-0076"> <h5 class="title">Random sequence generation</h5> <p>We assessed seven studies as low risk in this domain, as the authors referenced a randomisation schedule or the method of sequence generation was described in detail (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978;</a><a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005;</a><a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006;</a><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004;</a><a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007;</a><a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). For example, "Treatment randomisation was from a random numbers table, in blocks of four" (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>). </p> <p>We assessed the remaining eight studies as unclear risk for this domain because methods of random sequence generation were not described (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989;</a><a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014;</a><a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997;</a><a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983;</a><a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998;</a><a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> </section> <section id="CD009612-sec-0077"> <h5 class="title">Allocation concealment</h5> <p>The method of allocation concealment was poorly described, or insufficient detail was provided to enable definitive judgement on how concealment was achieved. We assessed five studies to be low risk in the allocation concealment domain (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978;</a><a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014;</a><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>). For example, "it was not possible to distinguish between combination product, monotherapies, and placebo granules…they had the same appearance, taste, and no noticeable smell" (<a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>). We assessed the remaining 10 studies as unclear risk because none provided the methods of allocation concealment in the text (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). </p> </section> </section> <section id="CD009612-sec-0078"> <h4 class="title">Blinding</h4> <section id="CD009612-sec-0079"> <h5 class="title">Blinding of participants and personnel</h5> <p>We assessed nine studies to be low risk in this domain as blinding of participants and key study personnel was ensured and it was unlikely that the blinding could have been broken (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). For example, "the randomisation code was not broken until all data, including delayed adverse events, had been allocated" (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). We assessed five studies as unclear risk because insufficient information was provided to permit a judgement of risk (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). We assessed the remaining study as high risk because the it was not blinded (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>). </p> </section> <section id="CD009612-sec-0080"> <h5 class="title">Blinding of outcome assessment</h5> <p>We assessed two studies to be low risk in this domain as both had stated methods of blinding of outcome assessment (<a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>). We assessed 12 studies as unclear risk, because there was insufficient information on the methods of blinding outcome assessment to permit judgement (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). We assessed the remaining study as high risk because it was not blinded (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>). </p> </section> </section> <section id="CD009612-sec-0081"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed 10 studies to be low risk for this domain. All participants, including those who discontinued, were accounted for in the text and the authors clearly indicated the numbers of remaining participants per treatment group (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). We assessed five studies as unclear risk (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). Numbers of remaining participants in each treatment group could not be ascertained. </p> </section> <section id="CD009612-sec-0082"> <h4 class="title">Selective reporting</h4> <p>We assessed 12 studies as low risk for selective reporting; these studies reported all intended outcomes (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). We assessed three studies to be at high risk of selective reporting bias (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>). <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a> reported only significant results in detail; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> reported NAC rather than NAR (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). </p> </section> <section id="CD009612-sec-0083"> <h4 class="title">Other potential sources of bias</h4> <p>We assessed four studies to be at low risk of other potential sources of bias; there was no evidence of pharmaceutical company funding or any other sources of bias identified in these studies (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>). We assessed 11 studies to be unclear risk; nine reported receiving pharmaceutical company (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) or commercial funding (<a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> was described very briefly and there was not enough detail to exclude the possibility of other bias. In <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>, participants were monitored for a six‐month period and had between one and four colds in this time. It is not clear from the text if participants with multiple colds were re‐randomised to a treatment group or continued on their original assigned treatment. </p> </section> </section> <section id="CD009612-sec-0084"> <h3 class="title" id="CD009612-sec-0084">Effects of interventions</h3> <p>See: <a href="./full#CD009612-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings for single‐dose nasal decongestant compared to placebo in adults with the common cold</a>; <a href="./full#CD009612-tbl-0002"><b>Summary of findings 2</b> Summary of findings for multi‐dose nasal decongestant compared to placebo in adults with the common cold</a>; <a href="./full#CD009612-tbl-0003"><b>Summary of findings 3</b> Summary of findings for all doses of nasal decongestant compared to placebo in adults with the common cold</a> </p> <p>See <a href="./full#CD009612-tbl-0001">summary of findings Table for the main comparison</a>, <a href="./full#CD009612-tbl-0002">summary of findings Table 2</a> and <a href="./full#CD009612-tbl-0003">summary of findings Table 3</a> for the primary outcome, subjective symptom scores for nasal congestion, and our main comparisons: single‐dose nasal decongestant versus placebo, multi‐dose nasal decongestant versus placebo and all doses of nasal decongestant versus placebo. </p> <p>There was considerable variability in the way outcomes were reported. The primary outcome, subjective nasal congestion, was measured on Likert or visual analogue scales (VAS) with different levels. Similarly, the secondary outcome, objective measurement of nasal congestion, was reported as the mean nasal airway resistance (NAR) (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>), the mean difference of NAR (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), the area under the curve (AUC) for the different NAR measurements from baseline to a certain follow‐up (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>), the mean nasal airway conductance (NAC) (<a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), and the least square mean of NAC (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). NAC is the inverse of NAR, however the methods of calculating the NAC were not described, making it impossible to recalculate the NAR or vice versa. Given these differences, we were unable to combine different statistical representations (e.g. mean and mean difference) as described in section 9.4.5 of the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0078" title="SterneJAC , EggerM , MoherD . Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Sterne 2011</a>). Therefore, results are presented for each outcome type separately and only SMDs are presented for all analyses to enable straightforward comparison of the effect size. In some studies a positive score indicated better nasal patency, whereas in other studies a negative score reflected better functioning. We transformed the negative scores (e.g. by multiplying by ‐1) so that for all comparisons a higher score reflected better functioning and studies could be combined. One study included more than one treatment arm (four different doses of the same nasal decongestant); we combined data from treatment arms that were similar and compared this group to the control group (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>). </p> <p>Heterogeneity was not greater than 90% for any analyses. We tested and reported differences between using fixed‐effect and random‐effects models, but we applied the random‐effects model as the final model for all analyses. The random‐effects model generates wider confidence intervals (CIs) than the fixed‐effect model (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). </p> <p>We present results for single and multi‐dose studies separately as well as all dosages combined for each outcome. We evaluated the effectiveness of a nasal decongestant compared to placebo approximately three hours after the last dose. We chose the timeframe of three hours because clinically we expect that a single or multi‐dose of nasal decongestant would have a similar effect, although it may not be as long lasting in the case of a single dose. Furthermore, most multi‐dose studies measured nasal decongestant effectiveness approximately three hours after the last dose. We discuss the results for this comparison only where both single and multi‐dose studies were available for the same outcome. Otherwise, we refer to the results for single or multi‐dose comparisons separately. Furthermore, some multi‐dose studies also reported outcomes after a single dose. In this comparison only the results after multiple doses are included otherwise the study would be counted twice. If possible, we also present results for studies that used an oral or topical decongestant separately and combined. </p> <section id="CD009612-sec-0085"> <h4 class="title">Primary outcomes</h4> <section id="CD009612-sec-0086"> <h5 class="title">1. Subjective symptom scores for nasal congestion (self‐reported scores of congestion)</h5> <section id="CD009612-sec-0087"> <h6 class="title">1.1. Single‐dose decongestant versus placebo</h6> <p>Six trials were single‐dose studies (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), two used a topical decongestant (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a>), and four used an oral decongestant (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Four of the nine multi‐dose studies also reported results after a single dose of nasal decongestant (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Of these multi‐dose studies, only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. As such, 10 studies compared a single dose of nasal decongestant with placebo, three of which used a topical decongestant. We have differentiated between single‐dose studies and studies reporting after a single dose. The effectiveness of the nasal decongestant was tested between 15 minutes and 10 hours after dosing. Given the large diversity in time points and methods we were unable to pool results. Results for all time points are reported in more detail for each study separately in the following sections. </p> <section id="CD009612-sec-0088"> <p><b>1.1.1 10 or 15 minutes after dosing</b></p> <p>Two studies measured the immediate effect of a nasal decongestant versus placebo 10 minutes (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, topical decongestant) or 15 minutes (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant) after a single administration. We were unable to pool results because <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> was excluded from all meta‐analyses. For both studies, the estimated standardised mean difference (SMD) between treatment and placebo was statistically significant and in favour of the treatment group (SMD 0.88, 95% CI 0.23 to 1.53; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant) (SMD 0.51, 95% CI 0.03 to 0.99; 106 participants; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, topical decongestant). The SMDs corresponded to a large and moderate effect respectively. </p> </section> <section id="CD009612-sec-0089"> <p><b>1.1.2 30 minutes after dosing</b></p> <p>Two studies assessed the effectiveness of treatment after 30 minutes (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Both studies used an oral decongestant. We were unable to pool results because <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> was excluded from all meta‐analyses. Only for <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> was the estimated SMD between treatment and placebo statistically significant and in favour of the treatment group (SMD 0.88, 95% CI 0.23 to 1.53; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant) (SMD 0.46, 95% CI ‐0.09 to 1.01; 52 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). SMDs corresponded to a large and small effect respectively. </p> </section> <section id="CD009612-sec-0090"> <p><b>1.1.3 One hour after dosing</b></p> <p>Three studies measured the effectiveness of a nasal decongestant subjectively one hour after dosing (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). However, we were unable to pool results. <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> used a topical decongestant and showed a small clinical effect that was not significantly different between treatment and placebo (SMD 0.22, 95% CI ‐0.25 to 0.70; 106 participants; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, topical decongestant). <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> used an oral decongestant and showed a large and moderate clinical effect that was statistically significant (SMD 0.88, 95% CI 0.23 to 1.54; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant) (SMD 0.72, 95% CI 0.15 to 1.28; 52 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0091"> <p><b>1.1.4 Two hours after dosing</b></p> <p>Three studies reported the effectiveness of a nasal decongestant compared to placebo two hours after treatment (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). All three studies used an oral decongestant. However, we were unable to pool results. In <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, the estimated SMD between treatment and placebo was not significant (SMD ‐0.10, 95% CI ‐0.66 to 0.47; 48 participants; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>, oral decongestant) (SMD 0.53 95% CI ‐0.03 to 1.08; 52 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). Only <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> showed a large clinical effect that was statistically significant (SMD 0.88, 95% CI 0.23 to 1.54; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0092"> <p><b>1.1.5 Three hours after dosing</b></p> <p>Four studies reported on the effectiveness of a nasal decongestant compared to placebo three hours after dosing (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). All four studies used an oral decongestant. Again, we were unable to pool results. <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> did not provide baseline values and there was insufficient information to standardise the results for comparison with the other studies. <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> found that the AUC of the VAS between 0 and 3 hours was significantly lower for the treatment group compared to placebo participants after a single dose (P = 0.029; difference in VAS AUC ‐8.33, 95%CI ‐15.80 to ‐0.85; 236 participants; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>, oral decongestant). However, <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> showed that the AUC of subjective congestion was not significantly different for the treatment group compared to the placebo group (SMD 0.22, 95% CI ‐0.05 to 0.49; 212 participants; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>, oral decongestant). In <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, the estimated SMD between treatment and placebo was not statistically significant (SMD 0.31, 95% CI ‐0.31 to 0.94; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant) (SMD 0.36, 95% CI ‐0.19 to 0.91; 52 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0093"> <p><b>1.1.6 Four hours after dosing</b></p> <p><a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> and <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> also reported on the effectiveness of a nasal decongestant compared to placebo four hours after dosing. <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> used a topical decongestant and <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> used an oral decongestant. We were unable to pool results because we excluded <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> from all meta‐analyses and both studies reported different outcome measures (mean and mean difference (MD)). Neither <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> (SMD 0.31, 95% CI ‐0.17 to 0.79; 106 participants; topical decongestant), nor <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> (SMD 0.40, 95% CI ‐0.23 to 1.02; 40 participants; oral decongestant) showed a statistically significant difference between the treatment and placebo groups. Furthermore, for both studies the SMD corresponded to a small clinical effect. </p> </section> <section id="CD009612-sec-0094"> <p><b>1.1.7 Other</b></p> <p><a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, who used a topical decongestant, also reported on the effectiveness of a single dose of a nasal decongestant seven hours after dosing. The difference between treatment and placebo group participants was not statistically significant (SMD 0.10, 95% CI ‐0.37 to 0.58; 106 participants; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, topical decongestant). </p> <p><a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> is a single‐dose study that used an oral decongestant. <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> used a cross‐over design and, therefore, these results were not included in the meta‐analyses. <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> reported that during the two to 10 hours observation period after dosing the mean score for subjective nasal congestion was better for the treatment group compared to placebo (P &lt; 0.01; 30 participants). </p> <p>Results reported by <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a> (oral decongestant) were not included in the meta‐analyses because insufficient details were provided to standardise the results, and it was not clear when NAR was measured. <a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a> reported that the NAR was improved in the treatment group (P &lt; 0.0001) but not in the control group (P = 0.98). This study was based on 82 participants. </p> </section> </section> <section id="CD009612-sec-0095"> <h6 class="title">1.2. Multi‐dose decongestant versus placebo</h6> <section id="CD009612-sec-0096"> <p><b>1.2.1 Oral and topical decongestants combined</b></p> <p>Subjective symptom scores were reported by five multi‐dose studies (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> reported the effectiveness about three hours after the last dose. Time since the last dose was not clear in <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>, <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> and <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>. We assumed that overall subjective symptom scores were measured about three hours after the last dose because other multi‐dose studies also used this timeframe. </p> <p>We were able to pool results for <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> and <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> (topical and oral decongestant respectively). These studies provided a mean score for subjective nasal congestion and the pooled SMD was statistically significant and in favour of the treatment group (SMD 0.49, 95% CI 0.07 to 0.92; 94 participants; two studies; <a href="./references#CD009612-fig-0004" title="">Analysis 1.1</a>). However, a SMD of 0.49 corresponds to a small clinical effect. </p> <p>The difference between studies that used oral or topical decongestants was not significant (P = 0.49). </p> <p>There was no major statistical heterogeneity as confirmed by an I² statistic of 0%. Nevertheless, we used a random‐effects model and this did not change our results. We judged the level of evidence to be of low quality because the pooled result was based on only two studies (imprecision) and there was possible risk of bias due to unclear reporting. </p> </section> <section id="CD009612-sec-0097"> <p><b>1.2.2 Oral decongestants</b></p> <p><a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> was the only study that reported a mean score and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> was the only study that reported the MD. Therefore we were unable to pool these results. In both studies, the difference between subjective congestion in the treatment versus placebo groups was not statistically significant (SMD 0.28, 95% CI ‐0.47 to 1.02; 33 participants; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>, oral decongestant) (SMD 0.15, 95% CI ‐0.12 to 0.42; 212 participants; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>, oral decongestant). </p> <p><a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a> and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> were not included in the meta‐analyses because insufficient details were provided to standardise results. <a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a> (140 participants) reported that there was a statistically significant improvement for subjective nasal congestion in the treatment group at the end of day one. However, no results for subjective nasal congestion were provided on days two and three and it was unclear if subjective nasal congestion in the treatment group was compared to the control group. <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> (238 participants) reported no statistically significant difference between treatment and placebo for the AUC of the VAS between 0 and 3 hours (P = 0.79) and between 0 and 4 hours (P = 0.75) after the last dose. Only over the three‐day period was there a statistically significant improvement for the mean difference in nasal congestion score for treatment compared to placebo. </p> </section> <section id="CD009612-sec-0098"> <p><b>1.2.3 Topical decongestants</b></p> <p>Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. In this study the difference between treatment and placebo was statistically significant and the SMD of 0.59 corresponded to a moderate clinical effect (SMD 0.59, 95% CI 0.08 to 1.11; 61 participants; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>, topical decongestant). </p> </section> </section> <section id="CD009612-sec-0099"> <h6 class="title">1.3. All doses of decongestants versus placebo</h6> <section id="CD009612-sec-0100"> <p><b>1.3.1 Oral and topical decongestants combined</b></p> <p>Four single‐dose studies (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) and five multi‐dose studies (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007;</a><a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) reported on subjective symptoms scores. All studies used an oral decongestant except <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>, which used a topical decongestant. However, pooling was possible for three studies only (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). </p> <p>These three studies reported a decline in the mean subjective symptom score for nasal congestion, and the pooled effect was statistically significant (SMD 0.44, 95% CI 0.11 to 0.78; 146 participants; three studies; <a href="./references#CD009612-fig-0008" title="">Analysis 2.1</a>). However, a SMD of 0.44 corresponds to a small effect. </p> <p>Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> used oral decongestants. The difference between studies that used oral or topical decongestants was not significant (P = 0.49). </p> <p>There was no major statistical heterogeneity as confirmed by an I² statistic of 0%. As such, using a random‐effects model did not change our results. We judged the evidence to be of moderate quality due to possible risk of bias. </p> </section> <section id="CD009612-sec-0101"> <p><b>1.3.2 Oral decongestants</b></p> <p>When only studies that used an oral decongestant were considered (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), the difference between treatment and placebo was no longer statistically significant (SMD 0.33, 95% CI ‐0.11 to 0.77; 85 participants; two studies; <a href="./references#CD009612-fig-0008" title="">Analysis 2.1</a>). </p> <p><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> reported the AUC for subjective nasal congestion; the pooled effect was very small and not statistically significant (SMD 0.11, 95% CI ‐0.14 to 0.35; 260 participants; two studies; <a href="./references#CD009612-fig-0008" title="">Analysis 2.1</a>). </p> <p>There was no major statistical heterogeneity as confirmed by an I² statistic of 0% for both the mean nasal congestion and the AUC. Using a random‐effects model did not change our results. We judged the evidence to be of low quality because of possible risk of bias due to unclear reporting and imprecision. </p> <p>None of the studies included in the meta‐analyses for the primary outcome measure reported intention‐to‐treat (ITT) analyses (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Only in <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> was the mean subjective score for nasal congestion significantly better for the treatment group compared to placebo. <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> randomised 61 participants but five people were not dosed or analysed; reasons for exclusion were not provided. In the other studies, participants were excluded from analysis because they were unable to perform the rhinomanometry (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>), had incomplete data (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>), were infected with a wild type rhinovirus, withdrew for personal reasons (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), or were unable to complete the study (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). </p> </section> <section id="CD009612-sec-0102"> <p><b>1.3.3 Topical decongestants</b></p> <p>Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. The difference between treatment and placebo was statistically significant and the SMD of 0.59 corresponded to a moderate clinical effect (SMD 0.59, 95% CI 0.08 to 1.11; 61 participants). </p> </section> </section> </section> <section id="CD009612-sec-0103"> <h5 class="title">2. Overall patient well‐being score (self‐reported)</h5> <p>The included trials did not report this outcome.</p> </section> </section> <section id="CD009612-sec-0104"> <h4 class="title">Secondary outcomes</h4> <section id="CD009612-sec-0105"> <h5 class="title">1. Objective measures of nasal airway resistance (NAR)</h5> <section id="CD009612-sec-0106"> <h6 class="title">1.1. Single‐dose decongestant versus placebo</h6> <p>Objective measures of NAR were tested between 15 minutes and 10 hours after dosing. Similar to subjective measures of NAR, we were unable to pool results. Therefore, we report results for all time points in more detail for each study. </p> <section id="CD009612-sec-0107"> <p><b>1.1.1 15 minutes after dosing</b></p> <p>Only <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> objectively measured the immediate effect of a nasal decongestant versus placebo 15 minutes after administration. This was assessed by the mean difference in NAR. The estimated SMD was small and the difference between the treatment and placebo groups was not statistically significant (SMD 0.42, 95% CI ‐0.21 to 1.04; 40 participants). This study used an oral decongestant. </p> </section> <section id="CD009612-sec-0108"> <p><b>1.1.2 30 minutes after dosing</b></p> <p>Two studies objectively assessed the effectiveness of oral decongestant treatment after 30 minutes (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). In both studies, the estimated SMD between treatment and placebo groups was not statistically significant (SMD 0.21 95% CI ‐0.41 to 0.83; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>), (SMD 0.08 95% CI ‐0.49 to 0.64; 48 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). </p> </section> <section id="CD009612-sec-0109"> <p><b>1.1.3 One hour after dosing</b></p> <p>Five studies objectively measured the effectiveness of a nasal decongestant one hour after dosing (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Of these, two used a topical decongestant (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>), and three used an oral decongestant (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). The reported outcome measurements varied considerably; mean scores and mean differences of NAR as well as mean scores and least square mean scores of NAC were reported. Therefore, we were unable to pool results. <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a> and <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> showed that the difference between treatment and placebo was statistically significant and corresponded to a moderate to large effect (SMD 0.65, 95% CI 0.14 to 1.15; 102 participants; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>, topical decongestant), (SMD 0.58, 95% CI 0.26 to 0.90; 153 participants; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>, oral decongestant), (SMD 1.06, 95% CI 0.52 to 1.59; 61 participants; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>, topical decongestant). In contrast, the estimated SMD between treatment and placebo was not statistically significant in <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> (SMD 0.54 95% CI ‐0.10 to 1.17; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant), (SMD 0.43 95% CI ‐0.14 to 1.00; 48 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0110"> <p><b>1.1.4 Two hours after dosing</b></p> <p>Three studies reported the effectiveness of oral nasal decongestant compared to placebo two hours after treatment (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Again, we were unable to pool results. <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> showed a large and statistically significant difference between treatment and placebo groups for the AUC from baseline to two hours (SMD 0.88, 95% CI 0.28 to 1.47; 48 participants; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>, oral decongestant). However, the estimated SMD between treatment and placebo was not statistically significant in <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> and <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> (SMD 0.27, 95% CI ‐0.35 to 0.89; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant), (SMD 0.17, 95% CI ‐0.40 to 0.74; 48 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0111"> <p><b>1.1.5 Three hours after dosing</b></p> <p>Four studies reported on the effectiveness of a nasal decongestant compared to placebo three hours after dosing (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Only <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> used a topical decongestant and showed a large and statistically significant difference for mean NAR between treatment and placebo, in favour of the treatment group (SMD 0.74, 95% CI 0.23 to 1.25; 102 participants). None of the other studies showed a statistically significant difference between treatment and placebo (SMD 0.28, 95% CI ‐0.34 to 0.90; 40 participants; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>, oral decongestant), (SMD 0.20, 95% CI ‐0.07 to 0.47; 212 participants; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>, oral decongestant), (SMD ‐0.30 95% CI ‐0.87 to 0.27; 48 participants; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, oral decongestant). </p> </section> <section id="CD009612-sec-0112"> <p><b>1.1.6 Four hours after dosing</b></p> <p>Three studies reported on the effectiveness of an oral nasal decongestant compared to placebo four hours after dosing (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>). <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> was excluded from all meta‐analyses; all three studies reported different outcome measures (mean, MD and AUC) so we were unable to pool results. Only <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a> showed that the AUC of the NAC measurements between baseline and four hours was significantly better for the treatment group compared to the placebo group (SMD 0.54, 95% CI 0.21 to 0.86; 153 participants). The SMD corresponded to a moderate clinical effect. <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> (SMD 0.40, 95% CI ‐0.23 to 1.02; 40 participants) and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> (SMD 0.19, 95% CI ‐0.06 to 0.45; 236 participants) did not report a statistically significant difference between the treatment and placebo group. </p> </section> <section id="CD009612-sec-0113"> <p><b>1.1.6 Other</b></p> <p>Only <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> reported the effectiveness of a single dose of a nasal decongestant up to seven hours after dosing. This study used a topical decongestant and showed a small difference between treatment and placebo that was not statistically significant (SMD 0.36, 95% CI ‐0.14 to 0.86; 102 participants). </p> <p><a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>, a single‐dose oral decongestant study that used a cross‐over design, involved 30 participants. It was not included in the meta‐analyses. <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> found that NAR worsened in the placebo group whereas it improved in the treatment group; this difference was statistically significant (P &lt; 0.02). </p> </section> </section> <section id="CD009612-sec-0114"> <h6 class="title">1.2. Multi‐dose decongestant versus placebo</h6> <section id="CD009612-sec-0115"> <p><b>1.2.1 Oral and topical decongestants combined</b></p> <p>Four multi‐dose studies reported objective measurements of nasal congestion (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). All studies except <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used an oral decongestant. Objective measurements of nasal congestion were represented as mean NAR (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>), the AUC for NAR (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>), the mean NAC (<a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>), and the least square mean of NAC (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). As all four studies reported different outcome measures, we were unable to pool results. <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a> and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> reported the effectiveness of a nasal decongestant three hours after the last dose, and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> measured this four hours after the last dose. Timing since last dose was not clear in <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>. Therefore, we report the effectiveness of multi‐dose decongestants assessed approximately three hours after the last dose. </p> </section> <section id="CD009612-sec-0116"> <p><b>1.2.2 Oral decongestants</b></p> <p>In <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> (SMD 0.11, 95% CI ‐0.14 to 0.37; 230 participants), <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a> (SMD 0.23, 95% CI ‐0.39 to 0.86; 40 participants) and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> (SMD 0.10, 95% CI ‐0.17 to 0.37; 212 participants) the effect of multiple doses of oral decongestants on objective measurements of nasal congestion was not statistically significant. </p> </section> <section id="CD009612-sec-0117"> <p><b>1.2.3 Topical decongestants</b></p> <p>Of the four studies that reported objective measurements of nasal congestion, <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> was the only study that used a topical decongestant and showed a statistically significant effect of multiple doses of nasal decongestant on objective measurements of nasal congestion: in this study expressed as the least square mean of NAC (SMD 0.89, 95% CI 0.36 to 1.41; 61 participants). The SMD of 0.89 corresponded to a significant clinical effect. </p> </section> </section> <section id="CD009612-sec-0118"> <h6 class="title">1.3. All doses of decongestants versus placebo</h6> <section id="CD009612-sec-0119"> <p><b>1.3.1 Oral and topical decongestants combined</b></p> <p>In total, four single‐dose (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) and four multi‐dose studies (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>) reported on objective measures of NAR. Only one single‐dose study (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>) and one multi‐dose study (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) used a topical decongestant. Pooling was possible for four studies only (<a href="./references#CD009612-fig-0010" title="">Analysis 2.3</a>): two single‐dose studies (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>) and two multi‐dose studies (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). </p> <p>Two studies reported a reduced mean NAR compared with placebo (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>), but the reduction was small and not statistically significant (SMD 0.39, 95% CI ‐0.22 to 0.99; 332 participants; two studies; <a href="./references#CD009612-fig-0010" title="">Analysis 2.3</a>). <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> used a topical decongestant and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> used an oral decongestant. The difference between studies that used an oral or topical decongestants was statistically significant (P = 0.03); the effect of treatment was significant in <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> (topical decongestant) and not significant in <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> (oral decongestant). However, each subgroup only included one study. </p> <p>There seemed to be considerable heterogeneity as shown by an I² statistic of 78%. The different measurement instruments probably explain the high heterogeneity; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> measured NAR with anterior rhinomanometry in the left nostril whereas <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> measured NAR with posterior rhinomanometry. We applied a random‐effects model because this changed the interpretation of the results from statistically significant to not statistically significant. </p> </section> <section id="CD009612-sec-0120"> <p><b>1.3.2. Oral decongestants</b></p> <p><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> used an oral decongestant and reported the AUC for NAR. Their pooled effect was not statistically significant (SMD 0.44, 95% CI ‐0.32 to 1.20; 260 participants; two studies; <a href="./references#CD009612-fig-0010" title="">Analysis 2.3</a>). </p> <p>For the pooled effect of the AUC for NAR, there seemed to be considerable heterogeneity as shown by an I² statistic of 82%. Interestingly, <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> were conducted at the same institution with the same research team. Both assessed the effectiveness of pseudoephedrine in a similar population. The only differences between the studies were the dosage and the measurement instrument; <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> was a single‐dose study and NAR was measured with acoustic rhinomanometry, whereas <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> was a multi‐dose study, with NAR being measured by posterior rhinomanometry. We applied a random‐effects model because this changed the interpretation of the results from statistically significant to not statistically significant. </p> </section> <section id="CD009612-sec-0121"> <p><b>1.3.3 Topical decongestant</b></p> <p>Only <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> and <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> reported the mean NAR whereas <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> reported the least square mean of NAC. Therefore, we were unable to pool results. Both studies showed a large and statistically significant difference between treatment and placebo, in favour of the treatment group (SMD 0.74, 95% CI 0.23 to 1.25; 102 participants; <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>), (SMD 0.89, 95% CI 0.36 to 1.41; 61 participants; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). </p> </section> </section> </section> <section id="CD009612-sec-0122"> <h5 class="title">2. Adverse events</h5> <section id="CD009612-sec-0123"> <h6 class="title">2.1. Single‐dose decongestant versus placebo</h6> <p>Two single‐dose trials reported adverse events (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); both used an oral decongestant. <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> reported no adverse events in either the treatment or the placebo group. Results from <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> were not included in the meta‐analysis because this study used a cross‐over study design and several events per patient were reported. Overall, 32 and 21 events were reported in the treatment and placebo groups respectively; this was not statistically significant. </p> </section> <section id="CD009612-sec-0124"> <h6 class="title">2.2. Multi‐dose decongestant versus placebo</h6> <section id="CD009612-sec-0125"> <p><b>2.2.1 Oral and topical decongestants combined</b></p> <p>Adverse events were reported by seven multi‐dose studies (<a href="./references#CD009612-fig-0005" title="">Analysis 1.2</a>) (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). All studies except <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used an oral decongestant. With the exception of <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>, all studies reported specific adverse events. However, the adverse events differed among studies and ranged from vomiting and dry mouth, to lethargy, dizziness, pain and mouth ulcers. In <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>, adverse events were not clearly described in the original paper, but these were included in the Cochrane Review by the same authors (<a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a>); therefore, we used these numbers in our review as well. </p> <p>We only reported the specific type of adverse event if this was reported by more than one study. </p> </section> <section id="CD009612-sec-0126"> <p><b>All adverse events</b></p> <p>Seven studies reported the total number of participants with adverse events (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). In both treatment and placebo arms, 13% of participants reported an adverse event. The chance of having an adverse event was slightly lower for treatment group participants. However, the difference with the placebo was not statistically significant (OR 0.98, 95% CI 0.68 to 1.40; 1195 participants; seven studies; <a href="./references#CD009612-fig-0005" title="">Analysis 1.2</a>). </p> <p>The difference between studies that used an oral or topical decongestant was not significant (P = 0.68). </p> <p>For the pooled effect of all adverse events there was no clear heterogeneity given the I² statistic of 0%. We used a random‐effects model throughout all analyses for adverse events and this did not change the interpretation of the results. </p> <p>We judged the evidence for all adverse events to be of low quality because of possible risk of bias due to unclear reporting and lack of precision (wide confidence interval). </p> </section> <section id="CD009612-sec-0127"> <p><b>Insomnia or difficulty sleeping</b></p> <p>Four studies reported the incidence of insomnia or difficulty sleeping (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); all used an oral decongestant. These results are reported in <i>2.2.2 Oral decongestants.</i> </p> </section> <section id="CD009612-sec-0128"> <p><b>Headache</b></p> <p>Headache was reported by three studies (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Neither individual studies nor the pooled estimate showed a statistically significant difference between treatment and placebo group participants (OR 0.89, 95% CI 0.23 to 3.37; 511 participants; three studies; <a href="./references#CD009612-fig-0007" title="">Analysis 1.4</a>). Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant. </p> <p>The difference between studies that used an oral or topical decongestant was not significant (P = 0.14). </p> <p>There seemed to be moderate heterogeneity given the I² statistic of 34%. We used a random‐effects model and this did not change the interpretation or the results. </p> </section> <section id="CD009612-sec-0129"> <p><b>2.2.2 Oral decongestants</b></p> </section> <section id="CD009612-sec-0130"> <p><b>All adverse events</b></p> <p>Six studies that used an oral decongestant reported total numbers of participants with adverse events (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). The difference with placebo was not statistically significant (OR 0.95, 95% CI 0.65 to 1.39; 1134 participants; six studies; <a href="./references#CD009612-fig-0005" title="">Analysis 1.2</a>). </p> <p>For the pooled effect of all adverse events there was no clear heterogeneity given the I² statistic of 0%. We used a random‐effects model for all analyses of adverse events; this did not change the interpretation or the results. We judged the evidence for all adverse events to be of moderate quality because of possible risk of bias due to unclear reporting. </p> </section> <section id="CD009612-sec-0131"> <p><b>Insomnia or difficulty sleeping</b></p> <p>Four studies reported the incidence of insomnia or difficulty sleeping (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); all used an oral decongestant. Two studies found a significantly lower risk in the treatment group compared to placebo (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>), but the pooled estimate was not statistically significant (OR 0.39, 95% CI 0.09 to 1.62; 623 participants; four studies; <a href="./references#CD009612-fig-0006" title="">Analysis 1.3</a>). </p> <p>There seemed to be moderate heterogeneity given the I² statistic of 50%. We used a random‐effects model and this changed the effect from statistically significant to not significant. </p> </section> <section id="CD009612-sec-0132"> <p><b>Headache</b></p> <p>Headache was reported by two studies that used an oral decongestant (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Neither the individual studies nor the pooled estimate showed a statistically significant difference between treatment and placebo groups (OR 0.58, 95% CI 0.19 to 1.84; 450 participants; two studies; <a href="./references#CD009612-fig-0007" title="">Analysis 1.4</a>). </p> <p>There was no clear heterogeneity given the I² statistic of 0%. We used a random‐effects model and this did not change the interpretation or the results. </p> </section> <section id="CD009612-sec-0133"> <p><b>2.2.3 Topical decongestants</b></p> </section> <section id="CD009612-sec-0134"> <p><b>All adverse events</b></p> <p>Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant and reported adverse events. In this study the difference between treatment and placebo was not statistically significant (OR 1.23, 95% CI 0.39 to 3.88; 61 participants). </p> </section> <section id="CD009612-sec-0135"> <p><b>Insomnia or difficulty sleeping</b></p> <p>None of the studies that used a topical decongestant reported insomnia or difficulty sleeping. </p> </section> <section id="CD009612-sec-0136"> <p><b>Headache</b></p> <p>Only <a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> used a topical decongestant and reported headache as an adverse event. In this study the difference between treatment and placebo groups was not statistically significant (OR 4.00, 95% CI 0.42 to 38.07; 61 participants). </p> </section> </section> <section id="CD009612-sec-0137"> <h6 class="title">2.3. All doses of decongestants versus placebo</h6> <p>Two single‐dose studies reported adverse events associated with oral decongestants (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> reported no events and <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> was excluded from meta‐analyses because it was a cross‐over study. Therefore, combining single‐dose and multi‐dose studies resulted in the same results for multi‐dose adverse events (<a href="./references#CD009612-fig-0005" title="">Analysis 1.2</a>). </p> </section> </section> <section id="CD009612-sec-0138"> <h5 class="title">3. Complications</h5> <p>None of the included studies reported this outcome.</p> </section> <section id="CD009612-sec-0139"> <h5 class="title">4. Time to full recovery</h5> <section id="CD009612-sec-0140"> <h6 class="title">4.1. Single‐dose decongestant versus placebo</h6> <p>The included single‐dose trials did not report this outcome.</p> </section> <section id="CD009612-sec-0141"> <h6 class="title">4.2. Multi‐dose decongestant versus placebo</h6> <p>Only one multi‐dose study reported the time to full recovery (<a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a>, 247 participants). <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> used a topical decongestant and showed that the mean time until full recovery was better for the treatment group (four days) compared to the placebo group (six days; P = 0.001). </p> </section> </section> <section id="CD009612-sec-0142"> <h5 class="title">5. Time to return to school/work</h5> <p>The included trials did not report this outcome.</p> </section> </section> <section id="CD009612-sec-0143"> <h4 class="title">Subgroup analyses</h4> <section id="CD009612-sec-0144"> <h5 class="title">1. Single‐dose decongestant versus placebo</h5> <section id="CD009612-sec-0145"> <h6 class="title">1.1 Children versus adults</h6> <p>We planned to compare studies in children aged up to 12 years compared with those aged over 12 years. However, none of the single‐dose studies included children so we were unable to perform this subgroup analysis. </p> </section> <section id="CD009612-sec-0146"> <h6 class="title">1.2 Oral versus topical</h6> <p>The other subgroup analysis, as specified a priori, was to compare oral versus nasal decongestants. Since we were unable to pool studies we could not perform this subgroup analysis. However, for each comparison in this review we report whether an oral or topical decongestant was used. </p> </section> </section> <section id="CD009612-sec-0147"> <h5 class="title">2. Multi‐dose decongestant versus placebo</h5> <section id="CD009612-sec-0148"> <h6 class="title">2.1 Children versus adults</h6> <p>We planned to compare studies in children aged up to 12 years compared with those aged over 12 years. However, none of the multi‐dose studies included children. <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> included people aged 12 years and above so excluded children. </p> </section> <section id="CD009612-sec-0149"> <h6 class="title">2.2 Oral versus topical</h6> <p>For the multi‐dose studies, we were only able to pool results for the primary outcome, subjective symptom scores for nasal congestion (three studies), and adverse events (seven studies). Therefore, assessing the difference between oral versus topical nasal decongestants on subjective symptom scores for nasal congestion involved two studies that used an oral decongestant (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), and one that used a topical decongestant (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). The difference between studies that used an oral decongestant and the study that used a topical decongestant was not statistically significant (P = 0.45). Also for adverse events, there was only one study that used a topical decongestant (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>); all others used an oral decongestant (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). The difference between the pooled result for the oral decongestant versus the only study on the topical decongestant was not statistically significant (P = 0.68). </p> </section> </section> <section id="CD009612-sec-0150"> <h5 class="title">3. All doses of decongestants versus placebo</h5> <section id="CD009612-sec-0151"> <h6 class="title">3.1 Children versus adults</h6> <p>We planned to compare studies in children aged up to 12 years compared with those aged over 12 years. However, none of the studies included children. </p> </section> <section id="CD009612-sec-0152"> <h6 class="title">3.2 Oral versus topical</h6> <p>We were able to assess the impact of oral versus topical decongestants only for outcomes where we could pool results and there were both single and multi‐dose studies available. This was only possible for the primary outcome, subjective symptom scores, and the secondary outcome, objective measures of NAR. </p> <p>For the primary outcome of subjective symptom scores, three studies reported the mean score (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>), and two studies reported an AUC (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Since pooling of these two outcome measures was not appropriate we discuss both separately. For studies that reported the mean subjective symptom score, we compared the pooled effect of the two studies that used an oral decongestant (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) with the results of one study that used a topical decongestant (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). The difference between the two was not statistically significant (P = 0.45). For the two studies that used AUC as an outcome we were unable to assess differences between oral and topical decongestants because both used an oral decongestant. </p> <p>Similar to the subjective symptom scores, objective measures of NAR were reported as the mean (<a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>), and the AUC (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). Since <a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> and <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> both used an oral decongestant we were only able to assess the difference between <a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> and <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>, which used topical and oral decongestants respectively. The difference between oral and topical decongestants was statistically significant (P = 0.03). However, each subgroup only included one study. </p> <p>As for multi‐dose decongestants we indicated if results were based on studies using an oral or topical decongestant. These results are reported in more detail above. </p> </section> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD009612-sec-0153" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD009612-sec-0153">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD009612-sec-0195">Español</a> </li> </nav> </div> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD009612-sec-0153"></div> <section id="CD009612-sec-0154"> <h3 class="title" id="CD009612-sec-0154">Summary of main results</h3> <p>We compared the effectiveness of nasal decongestants administered as single and multiple doses to treat nasal congestion in people with the common cold. We included 15 trials and analyses were based on a total of 1838 participants. Nine studies used pseudoephedrine and three used oxymetazoline. Other decongestants included phenylpropanolamine, norephedrine and xylometazoline. The studies that used phenylpropanolamine or norephedrine were excluded from meta‐analyses because this drug is no longer available in most countries (<a href="./references#CD009612-bbs2-0057" title="FDA Public Health Advisory: Safety of Phenylpropanolamine. Federal Register 2012. http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm052236.htm (accessed 22 April 2016). ">FDA 2000</a>). There were large differences in reported outcomes. Reporting of study methods was limited in most studies. Therefore, pooling was only possible for a few studies. All studies, except one, included adult participants only (aged 18 years and over). <a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> included younger people (aged up to 12 years) but did not provide details on the mean age of participants. As such, the results of this review are applicable to adults only. </p> <p>We were unable to draw conclusions on the effectiveness of single‐dose decongestants because pooling was not possible due to the large diversity in measuring and reporting symptoms of congestion. For other outcome measures, such as overall patient well‐being and time to recovery, either no data or insufficient data were available. </p> <p>For multiple doses of decongestant, meta‐analysis was possible for subjective measures of congestion only (measured approximately three hours after the last dose). Subjective measures of congestion were significantly better for treatment group participants compared to placebo group participants. However, the clinical effect was small, and this result was based on two studies only (one topical and one oral decongestant) and involved a total of 88 participants. </p> <p>Hence, for multiple doses of a nasal decongestant it seems that there is a small beneficial effect on nasal congestion when measured subjectively. Although subjective measures of nasal congestion are probably the most relevant outcomes, since nasal decongestants are used for symptomatic relief only, it is not clear if this small effect is clinically relevant and sufficient to justify widespread use of decongestants (<a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a>). </p> <p>There were insufficient data to estimate differences in the efficacy of oral versus topical decongestants. Adverse events were reported in nine studies and the risk of adverse events in treatment group participants was not significantly different from people in the placebo group. It seems that short‐term use of nasal decongestants in adults with the common cold can be considered safe. </p> </section> <section id="CD009612-sec-0155"> <h3 class="title" id="CD009612-sec-0155">Overall completeness and applicability of evidence</h3> <p>We recognise that there were few included studies. In addition, because these studies were very heterogeneous in their approach to outcome measures, the number of studies that could be pooled for each outcome was even smaller, with most subgroup analyses only containing two studies. Hence, the generalisability of our results is very limited. </p> <p>With respect to adverse events it was surprising to note that none of the included multi‐dose studies investigated the problem of tachyphylaxis or rhinitis medicamentosa. This could be due to the limited follow‐up in most studies (between one and 10 days). Furthermore, the side effects profile of oral versus topical decongestants might differ; one might expect more systemic and delayed side effects with oral preparations. We were unable to assess this aspect because only one study that used a topical decongestant reported adverse effects. </p> <p>Twelve studies used subjective measures as outcomes, which are probably the most relevant outcomes to clinical applicability, because nasal decongestants are used for symptomatic relief. In addition, all studies, except one, included participants with community‐acquired common cold. </p> <p>The results are only applicable to an adult population because none of the studies included children aged 12 years or younger. </p> <p>Another concern about the applicability of the current evidence relates to the use of pseudoephedrine. Nine studies tested the effectiveness of pseudoephedrine; however, this has not been available since 2005 as an over‐the‐counter decongestant because it can be used to make methamphetamine (<a href="./references#CD009612-bbs2-0058" title="Information by drug class: Legal Requirements for the Sale and Purchase of Drug Products Containing Pseudoephedrine, Ephedrine, and Phenylpropanolamine. Federal Register 2005. http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm072423.htm (accessed 22 April 2016). ">FDA 2005</a>). Currently, pseudoephedrine is being replaced by phenylephrine as a way to control methamphetamine abuse. Despite phenylephrine being a common decongestant that is available over‐the‐counter, none of the studies in this review evaluated its effectiveness. </p> </section> <section id="CD009612-sec-0156"> <h3 class="title" id="CD009612-sec-0156">Quality of the evidence</h3> <p>For most outcomes we downgraded the quality of evidence to moderate or low due to the limited data available or poor 'Risk of bias' assessments. We included 15 studies, with a total of 1838 participants, but pooling was often not possible. When pooling was possible, results were often only based on two studies. All studies except one included adult participants and so the findings of our review cannot be generalised to children. We recognise that over half of the included studies were published before 2000, and that many of the studies do not provide sufficient methodological information to exclude risk of bias. Hence, for most studies, risk of bias is unclear. </p> </section> <section id="CD009612-sec-0157"> <h3 class="title" id="CD009612-sec-0157">Potential biases in the review process</h3> <p>Given the small number of included studies, it is possible that we did not find all relevant trials. Hence, publication bias cannot be definitively ruled out, which may lead to overestimation of the treatment effect. For example, we found four studies that were relevant for this review, but no results were available. Two are completed trials with no published results (<a href="./references#CD009612-bbs2-0041" title="NCT00452270 . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of xylometazoline in subjects with a common cold. https://clinicaltrials.gov/ct2/show/NCT00452270 (accessed 6 October 2015). ">NCT00452270</a>; <a href="./references#CD009612-bbs2-0042" title="NCT01062360 . A pivotal, placebo controlled, phase III study to compare efficacy and tolerability of a fixed combination, containing 500 mg ASA and 30 mg pseudoephedrine, in comparison to its single components in patients with sore throat and nasal congestion. https://clinicaltrials.gov/ct2/show/NCT01062360 (accessed 6 October 2015). ">NCT01062360</a>), and a third, although originally registered in 2007, is stated to be ongoing (<a href="./references#CD009612-bbs2-0043" title="EUCTR2006‐006690‐25‐GB . A double‐blind, randomized, parallel group, placebo controlled study, evaluating the decongestant effect, time to onset, duration of effect and impact on sleep and general well‐being of otrivin F2 in subjects with a common cold ‐ a study to evaluate the decongestant effect of Otrivin F2. https://www.clinicaltrialsregister.eu/ctr‐search/trial/2006‐006690‐25/GB (accessed 6 October 2015). ">EUCTR2006‐006690‐25‐GB</a>). The fourth study is also ongoing; it started in 2012, but the estimated completion date recently changed from April 2015 to May 2016 (<a href="./references#CD009612-bbs2-0044" title="NCT01744106 . A multicenter study of pseudoephedrine for the temporary relief of nasal congestion in children with the common cold. https://clinicaltrials.gov/ct2/show/NCT01744106 (accessed 6 October 2015). ">NCT01744106</a>). </p> <p>This review was conducted as outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD009612-bbs2-0066" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org. ">Higgins 2011</a>). We searched several databases and three authors (LD, LG, NM) independently selected studies and extracted data, thus minimising the risk of introducing bias during the review process. </p> </section> <section id="CD009612-sec-0158"> <h3 class="title" id="CD009612-sec-0158">Agreements and disagreements with other studies or reviews</h3> <p>Our results are in line with those of other systematic reviews and meta‐analyses. In a similar, but older, Cochrane Review on nasal decongestants for the common cold, <a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a> concluded that nasal decongestants are modestly effective for the short‐term relief of congestion in adults. Two hours after dosing, a significant decrease in patient‐reported symptoms for treatment versus placebo was described. Similar to our findings, the effects were small and although statistically significant, it is not clear if the reduction in symptoms is clinically relevant and sufficient to justify widespread use of decongestants (<a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a>). </p> <p>Several other reviews on nasal decongestants for the common cold have also been published (e.g. <a href="./references#CD009612-bbs2-0046" title="AllanGM , ArrollB . Prevention and treatment of the common cold: making sense of the evidence. Canadian Medical Association Journal2014;186(3):190‐9. [DOI: 10.1503/cmaj.121442] ">Allan 2014</a>; <a href="./references#CD009612-bbs2-0047" title="ArrollB . Non‐antibiotic treatments for upper‐respiratory tract infections (common cold). Respiratory Medicine2005;99:1477‐84. ">Arroll 2005</a>; <a href="./references#CD009612-bbs2-0048" title="ArrollB . Common cold. BMJ Clinical Evidence 2011. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3275147/pdf/2011‐1510.pdf (accessed 3 November 2015). ">Arroll 2011</a>; <a href="./references#CD009612-bbs2-0070" title="MeltzerEO , CaballeroF , FromerLM , KrouseJH , ScaddingG . Treatment of congestion in upper respiratory diseases. International Journal of General Medicine2010;3:69‐91. ">Meltzer 2010</a>). Generally, their conclusions were based on the Cochrane Reviews <a href="./references#CD009612-bbs2-0081" title="TavernerD , LatteJ , DraperM . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2004, Issue 3. [DOI: 10.1002/14651858.CD001953.pub2] ">Taverner 2004</a> and <a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a>, or more recent studies that were included in this review. Accordingly, the results and conclusions are similar and in line with this review. </p> <p><a href="./references#CD009612-bbs2-0068" title="KollarC , SchneiderH , WaksmanJ , KrusinskaE . Meta‐analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. Clinical Therapeutics2007;29:1057‐70. ">Kollar 2007</a> investigated the effectiveness of a single 10 mg dose of phenylephrine compared to placebo. <a href="./references#CD009612-bbs2-0068" title="KollarC , SchneiderH , WaksmanJ , KrusinskaE . Meta‐analysis of the efficacy of a single dose of phenylephrine 10 mg compared with placebo in adults with acute nasal congestion due to the common cold. Clinical Therapeutics2007;29:1057‐70. ">Kollar 2007</a> showed that a single oral dose of phenylephrine significantly improved acute nasal congestion. However, it must be noted that the meta‐analyses in this review were almost completely based on small unpublished studies conducted between 1968 and 1975, which were included in a monograph by the US Food and Drug Administration (FDA). According to <a href="./references#CD009612-bbs2-0054" title="EcclesR . Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. British Journal of Clinical Pharmacology2007;63(1):10‐4. [DOI: 10.1111/j.1365‐2125.2006.02833.x] ">Eccles 2007</a>, the studies included in the FDA report were in‐house studies provided by representatives of pharmaceutical companies (<a href="./references#CD009612-bbs2-0054" title="EcclesR . Substitution of phenylephrine for pseudoephedrine as a nasal decongestant. An illogical way to control methamphetamine abuse. British Journal of Clinical Pharmacology2007;63(1):10‐4. [DOI: 10.1111/j.1365‐2125.2006.02833.x] ">Eccles 2007</a>). </p> <p>Another review on xylometazoline (alone and in combination) concluded that xylometazoline provides fast and effective relief from nasal congestion (<a href="./references#CD009612-bbs2-0056" title="EcclesR , MartenssonK , ChenSC . Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Current Medical Research &amp; Opinion2010;26:889‐99. ">Eccles 2010</a>). However, this review included only four studies and did not include a meta‐analysis. We included only one study that used xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>). Hence, we were unable to formulate firm conclusions about the effectiveness of this medication. Furthermore, it was beyond the scope of our review to evaluate the effectiveness of different nasal decongestants individually. </p> <p>The Cochrane Review on combination drugs for the common cold (oral antihistamine‐decongestant‐analgesic combinations) found that the effect on individual symptoms is small, "probably too small to be clinically relevant" (<a href="./references#CD009612-bbs2-0050" title="DeSutterAIM , vanDrielML , KumarAA , LesslarO , SkrtA . Oral antihistamine‐decongestant‐analgesic combinations for the common cold. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004976.pub3] ">De Sutter 2012</a>). The lack of evidence in children was also confirmed by other studies on decongestants alone and combination products (<a href="./references#CD009612-bbs2-0046" title="AllanGM , ArrollB . Prevention and treatment of the common cold: making sense of the evidence. Canadian Medical Association Journal2014;186(3):190‐9. [DOI: 10.1503/cmaj.121442] ">Allan 2014</a>; <a href="./references#CD009612-bbs2-0047" title="ArrollB . Non‐antibiotic treatments for upper‐respiratory tract infections (common cold). Respiratory Medicine2005;99:1477‐84. ">Arroll 2005</a>; <a href="./references#CD009612-bbs2-0050" title="DeSutterAIM , vanDrielML , KumarAA , LesslarO , SkrtA . Oral antihistamine‐decongestant‐analgesic combinations for the common cold. Cochrane Database of Systematic Reviews2012, Issue 2. [DOI: 10.1002/14651858.CD004976.pub3] ">De Sutter 2012</a>). </p> <p>In terms of the risk of side effects our results were in agreement with other reviews and studies; the incidence of side effects with short‐term use of decongestants is low and side effects are mostly mild to moderate (e.g. insomnia and headache) (<a href="./references#CD009612-bbs2-0046" title="AllanGM , ArrollB . Prevention and treatment of the common cold: making sense of the evidence. Canadian Medical Association Journal2014;186(3):190‐9. [DOI: 10.1503/cmaj.121442] ">Allan 2014</a>; <a href="./references#CD009612-bbs2-0056" title="EcclesR , MartenssonK , ChenSC . Effects of intranasal xylometazoline, alone or in combination with ipratropium, in patients with common cold. Current Medical Research &amp; Opinion2010;26:889‐99. ">Eccles 2010</a>; <a href="./references#CD009612-bbs2-0082" title="TavernerD , LatteJ . Nasal decongestants for the common cold. Cochrane Database of Systematic Reviews2007, Issue 1. [DOI: 10.1002/14651858.CD001953.pub3] ">Taverner 2007</a>). Although we did not identify data on the safety of nasal decongestants in children, there are reports of adverse events after single use of nasal decongestant. For example, the FDA published a warning in 2012 about serious adverse events after ingestion of over‐the‐counter nasal sprays containing oxymetazoline by children under the age of six years (<a href="./references#CD009612-bbs2-0059" title="FDA Drug Safety Communication: Serious adverse events from accidental ingestion by children of over‐the‐counter eye drops and nasal sprays. Federal Register 2012. http://www.fda.gov/Drugs/DrugSafety/ucm325257.htm (accessed 3 November 2015). ">FDA 2012</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD009612-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram" data-id="CD009612-fig-0001" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages for all included studies" data-id="CD009612-fig-0002" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages for all included studies </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study" data-id="CD009612-fig-0003" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multi‐dose decongestant versus placebo, Outcome 1 Primary outcome: subjective symptom score (mean)." data-id="CD009612-fig-0004" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Multi‐dose decongestant versus placebo, Outcome 1 Primary outcome: subjective symptom score (mean). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multi‐dose decongestant versus placebo, Outcome 2 Secondary outcome: all adverse events." data-id="CD009612-fig-0005" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Multi‐dose decongestant versus placebo, Outcome 2 Secondary outcome: all adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multi‐dose decongestant versus placebo, Outcome 3 Secondary outcome: adverse events ‐ insomnia/difficulty sleeping." data-id="CD009612-fig-0006" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Multi‐dose decongestant versus placebo, Outcome 3 Secondary outcome: adverse events ‐ insomnia/difficulty sleeping. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Multi‐dose decongestant versus placebo, Outcome 4 Secondary outcome: adverse events ‐ headache." data-id="CD009612-fig-0007" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Multi‐dose decongestant versus placebo, Outcome 4 Secondary outcome: adverse events ‐ headache. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-002-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-002-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 All doses of decongestants versus placebo, Outcome 1 Primary outcome: subjective symptom score (mean)." data-id="CD009612-fig-0008" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2 All doses of decongestants versus placebo, Outcome 1 Primary outcome: subjective symptom score (mean). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-002-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-002-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 All doses of decongestants versus placebo, Outcome 2 Primary outcome: subjective symptom score (AUC)." data-id="CD009612-fig-0009" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.2</div> <div class="figure-caption"> <p>Comparison 2 All doses of decongestants versus placebo, Outcome 2 Primary outcome: subjective symptom score (AUC). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-002-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-002-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 All doses of decongestants versus placebo, Outcome 3 Secondary outcome: objective NAR (mean)." data-id="CD009612-fig-0010" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.3</div> <div class="figure-caption"> <p>Comparison 2 All doses of decongestants versus placebo, Outcome 3 Secondary outcome: objective NAR (mean). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD009612-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/urn:x-wiley:14651858:media:CD009612:CD009612-CMP-002-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_t/tCD009612-CMP-002-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 2 All doses of decongestants versus placebo, Outcome 4 Secondary outcome: objective NAR (AUC)." data-id="CD009612-fig-0011" src="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.4</div> <div class="figure-caption"> <p>Comparison 2 All doses of decongestants versus placebo, Outcome 4 Secondary outcome: objective NAR (AUC). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/media/CDSR/CD009612/image_n/nCD009612-CMP-002-04.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD009612-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for single‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should a single dose of decongestant in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: single‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with single‐dose decongestant</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>subjective symptom score ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>540 (4 RCTs, oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); Phenylpropanolamine (<a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>overall patient well‐being ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome:<br/> all adverse events </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Two single‐dose trials reported adverse events (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>). Both used an oral decongestant. <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> (pseudoephedrine versus placebo) reported no adverse events in either the treatment or the placebo group; we did not include <a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> (norephedrine versus placebo) results in the meta‐analysis because a cross‐over study design was used and several events per patient were reported </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82 (2 RCTs, oral)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Norephedrine (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>); Pseudoephedrine (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <b>CI:</b> confidence interval; <b>NAR:</b> nasal airway resistance; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings for single‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009612-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for multi‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should multiple doses of decongestant in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: multi‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> <p><b>Measure of effect:</b> we transformed results from all studies to ensure that higher scores represent better functioning. We standardised results using the standardised mean differences (SMD). As such differences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a large clinical effect. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with multi‐dose decongestant</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐7 to ‐35.79</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.49 standard units <b>better</b> in the treatment group (95% CI 0.07 to 0.92; <b>P value 0.02</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>1 2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>); pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: overall patient well‐being</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events</p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.98<br/> (0.68 to 1.40) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1195<br/> (7 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); triprolidine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>); xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>126 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>124 per 1000</b> <br/> (89 to 168) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>OR 0.95<br/> (0.65 to 1.39) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>1134<br/> (6 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>; <a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a>; <a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a>; <a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>); triprolidine (<a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>121 per 1000</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>115 per 1000</b> <br/> (82 to 160) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Secondary outcome: all adverse events<br/> <b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p>Study population</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>OR:</b> odds ratio; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>1</sup>Downgraded because of possible risk of bias; random sequence generation and allocation concealment was not clear in both studies. </p> <p><sup>2</sup>Downgraded because data came from only two studies. </p> <p><sup>3</sup>Downgraded because three studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), and the estimate had a wide confidence interval (imprecision). </p> <p><sup>4</sup>Downgraded because two studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>), and the estimate had a wide confidence interval (imprecision). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings for multi‐dose nasal decongestant compared to placebo in adults with the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD009612-tbl-0003"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for all doses of nasal decongestant compared to placebo in adults with the common cold</span></div> <tbody> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Should a decongestant (any dose) in monotherapy be used for the common cold in adults?</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population</b>: adult patients with the common cold </p> <p><b>Settings</b>: common cold centres, universities and hospitals </p> <p><b>Intervention</b>: single‐dose or multi‐dose decongestant in monotherapy, oral and topical decongestants combined </p> <p><b>Comparison</b>: placebo </p> <p><b>Measure of effect:</b> we transformed results from all studies to ensure that higher scores represent better functioning. We standardised results using the standardised mean differences (SMD). As such differences are expressed in standardised units. As a rough guide, a SMD of 0.2 to 0.49 represents a small, 0.5 to 0.79 a moderate and ≥ 0.8 a large clinical effect. </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Anticipated absolute effects<sup>*</sup> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>№ of participants<br/> (studies)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="left" class="table-header" colspan="1" rowspan="2" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with placebo</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Risk with all doses of decongestants</b> </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐2.54 to ‐35.79</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.44 standard units <b>better</b> in the treatment group (95% CI 0.11 to 0.78; <b>P value 0.01</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146<br/> (3 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> MODERATE <sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>); xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean subjective symptom score ranged from ‐2.54 to ‐7</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.33 standard units <b>better</b> in the treatment group (95% CI ‐0.11 to 0.77; <b>P value 0.14</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>2 3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>; <a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (mean) ‐ 3 hours after dosing</p> <p><b>Topical</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61<br/> (1 RCT) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Insufficient data to pool results</p> <p>Xylometazoline (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome: subjective symptom score (AUC) ‐ 3 hours after dosing<br/> <b>Oral</b> </p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The unstandardised mean AUC for the subjective symptom score ranged from 22 to ‐77.45</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>Subjective nasal congestion was 0.11 standard units <b>better</b> in the treatment group (95% CI ‐0.14 to 0.35; <b>P value 0.39</b>) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260<br/> (2 RCTs) </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> LOW <sup>3 4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>None of the included studies that used a topical decongestant reported the AUC for subjective symptoms of congestion </p> <p>Pseudoephedrine (<a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a>; <a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>) </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome:</p> <p>overall patient well‐being</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>(0 studies)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Not reported</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Secondary outcome:<br/> All adverse events </p> </td> <td align="left" class="table-tint table-highlight" colspan="3" rowspan="1" valign="top"> <p>Only 2 single‐dose studies reported adverse events. One study reported no events (<a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a>, pseudoephedrine) and the other was excluded from meta‐analyses as this was a cross‐over study (<a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a>, norephedrine). Combining single‐dose and multi‐dose studies would not change the results of the multi‐dose analyses. </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p>*<b>The risk in the intervention group</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> <br/> <b>CI:</b> confidence interval; <b>AUC:</b> area under the curve; <b>NAR:</b> nasal airway resistance; <b>RCT:</b> randomised controlled trial </p> </td> </tr> <tr class="separated"> <td align="left" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>GRADE Working Group grades of evidence</b> <br/> <b>High quality:</b> We are very confident that the true effect lies close to that of the estimate of the effect<br/> <b>Moderate quality:</b> We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different<br/> <b>Low quality:</b> Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect<br/> <b>Very low quality:</b> We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>¹Downgraded because two studies had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a>; <a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> <p>²Downgraded because one study had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a>). </p> <p>³Downgraded because data came from only two studies.</p> <p>⁴Downgraded because one study had unclear risk of bias on five out of seven domains (<a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a>). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 3.</span> <span class="table-title">Summary of findings for all doses of nasal decongestant compared to placebo in adults with the common cold</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD009612-tbl-0004"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Reference</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Single/multi‐dose study</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Decongestant</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Mode of administration</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Follow‐up</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b> Comments</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0001" title="AkerlundA , KlintT , OlenL , RundcrantzH . Nasal decongestant effect of oxymetazoline in the common cold: an objective dose‐response study in 106 patients. Journal of Laryngology &amp; Otology1989;103(8):743‐6. ">Akerlund 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0008" title="FergusonEA , EcclesR . Changes in nasal nitric oxide concentration associated with symptoms of common cold and treatment with a topical nasal decongestant. Acta Oto‐Laryngologica1997;117(4):614‐7. ">Ferguson 1997</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because insufficient details were provided to standardise the results </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0009" title="GronborgH , WintherB , BrofeldtS , BorumP , MygindN . Effects of oral norephedrine on common cold symptoms. Rhinology1983;21(1):3‐12. ">Gronborg 1983</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Norephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because a cross‐over design was used and because norephedrine (phenylpropanolamine) is no longer available on the market </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0003" title="CohenBM . Clinical correlants of changes in nasal flow/resistance (Rn) measurements. Allergologia et Immunopathologia1978;6(3):217‐23. ">Cohen 1978</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Phenylpropanolamine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Excluded from meta‐analyses because phenylpropanolamine is no longer available on the market </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0015" title="TavernerD , DanzC , EconomosD . The effects of oral pseudoephedrine on nasal patency in the common cold: a double‐blind single‐dose placebo‐controlled trial. Clinical Otolaryngology and Allied Sciences1999;24(1):47‐51. ">Taverner 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0011" title="LatteJ , TavernerD , SlobodianP , ShakibS . A randomized, double‐blind, placebo‐controlled trial of pseudoephedrine in coryza. Clinical and Experimental Pharmacology &amp; Physiology2004;31(7):429‐32. ">Latte 2004</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0006" title="EcclesR , ErikssonM , GarreffaS , ChenSC . The nasal decongestant effect of xylometazoline in the common cold. American Journal of Rhinology2008;22(5):491‐6. EcclesR , MartenssonK , StephenG , ChenS . A double‐blind, randomised, parallel group, placebo‐controlled study evaluating the nasal decongestant effect of xylometazoline in common cold [Abstract]. Primary Care Respiratory Journal2008;17(2):120. ">Eccles 2008</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Xylometazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Max 10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0004" title="EcclesR , JawadMSM , JawadSSM , AngelloJT , DruceHM . Efficacy and safety of single and multiple doses of pseudoephedrine in the treatment of nasal congestion associated with common cold. American Journal of Rhinology2005;19(1):25‐31. ">Eccles 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0005" title="EcclesR , JawadM , JawadS , RidgeD , NorthM , JonesE , et al. Efficacy of a paracetamol‐pseudoephedrine combination for treatment of nasal congestion and pain‐related symptoms in upper respiratory tract infection. Current Medical Research and Opinion2006;22(12):2411‐8. ">Eccles 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0007" title="EcclesR , VoelkerM . Analgesic and decongestant efficacy of the combination of aspirin with pseudoephedrine in patients with symptoms of upper respiratory tract infection. Clinical Pharmacology in Drug Development2014;3(2):118‐25. ">Eccles 2014</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0014" title="SperberSJ , SorrentinoJV , RikerDK , HaydenFG . Evaluation of an alpha agonist alone and in combination with a nonsteroidal antiinflammatory agent in the treatment of experimental rhinovirus colds. Bulletin of the New York Academy of Medicine1989;65(1):145‐60. ">Sperber 1989</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0002" title="ByeCE , CooperJ , EmpeyDW , FowleAS , HughesDT , LetleyE , et al. Effects of pseudoephedrine and triprolidine, alone and in combination, on symptoms of the common cold. BMJ1980;281(6234):189‐90. ">Bye 1980</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0010" title="JawadSS , EcclesR . Effect of pseudoephedrine on nasal airflow in patients with nasal congestion associated with common cold. Rhinology1998;36(2):73‐6. ">Jawad 1998</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 day</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0013" title="ReineckeS , TschaikinM . Investigation of the effect of oxymetazoline on the duration of rhinitis [Alpha‐Sympathomimetikum bessert nicht nur die nasale Obstruktion: Schnupfendauer wird verkürzt]. MMW Fortschritte der Medizin2005;147(41):46. ">Reinecke 2005</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oxymetazoline</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Topical</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD009612-bbs2-0012" title="LatteJ , TavernerD . Clinical trial of 3 days of treatment with oral pseudoephedrine for the common cold in the southern hemisphere. American Journal of Rhinology2007;21(4):452‐5. ">Latte 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Multiple</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pseudoephedrine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 days</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Study characteristics</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/full#CD009612-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009612-tbl-0005"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Multi‐dose decongestant versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: subjective symptom score (mean) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.07, 0.92]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [‐0.47, 1.02]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.08, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Secondary outcome: all adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1195</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.68, 1.40]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1134</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.95 [0.65, 1.39]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.23 [0.39, 3.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secondary outcome: adverse events ‐ insomnia/difficulty sleeping <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>4</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>623</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.09, 1.62]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Secondary outcome: adverse events ‐ headache <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>511</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.89 [0.23, 3.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>450</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.58 [0.19, 1.84]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Odds Ratio (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>4.0 [0.42, 38.07]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Multi‐dose decongestant versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD009612-tbl-0006"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">All doses of decongestants versus placebo</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Primary outcome: subjective symptom score (mean) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>146</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [0.11, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.33 [‐0.11, 0.77]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>61</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.59 [0.08, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Primary outcome: subjective symptom score (AUC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.14, 0.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Secondary outcome: objective NAR (mean) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>332</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [‐0.22, 0.99]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>230</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.11 [‐0.14, 0.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Topical</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>102</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.23, 1.25]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Secondary outcome: objective NAR (AUC) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Oral</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>260</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Std. Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.44 [‐0.32, 1.20]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">All doses of decongestants versus placebo</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD009612.pub2/references#CD009612-tbl-0006">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD009612.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD009612-note-0007">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD009612-note-0013">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD009612-note-0005">Français</a> </li> <li class="section-language"> <a class="" href="hr#CD009612-note-0004">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ms#CD009612-note-0003">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="pl#CD009612-note-0006">Polski</a> </li> <li class="section-language"> <a class="" href="ru#CD009612-note-0002">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD009612-note-0001">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738735355000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738735355000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773978000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774074000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739774000000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009612\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009612\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009612\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD009612\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD009612\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738735355000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=kKvAiZoF&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009612.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD009612.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD009612.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD009612.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD009612.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740717622004"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009612.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740717622007"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD009612.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dbc676bb29371',t:'MTc0MDcxNzYyMi4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 